Moorestown, New Jersey, United States
BiotechVortex™
Vortexes are powerful and transformational centers of energy
The BiotechVortex™ section of this site was created when I started seeing an increase in partnerships, mergers, and co-operative agreements, in both the biotech and medtech sectors. Here we will highlight these partnerships/agreements/mergers, even when no specific products are identified.
BiotechVORTEX - First Group Page
BiotechVortex™ - Second Group Page
BiotechVortex™
Novadiscovery inks new clinical simulation collaboration with Takeda
Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance
Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance
Novadiscovery announces new clinical simulation collaboration with Takeda
Fri March 26, 2021 8:00 AM|GlobeNewswire
Novadiscovery announces new clinical simulation collaboration with Takeda
Lyon, France – 26 March, 2021 Novadiscovery (“NOVA”
About NOVA
NOVA is a leading health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development. The Company aims to improve R&D productivity and maximize patient outcomes by predicting the clinical benefit of a potential new drug candidate through computer simulation, ahead of human trials.
NOVA’s innovative approach leverages disease modeling and simulation expertise accumulated over the past decade and combines mathematical models of diseases and potential new treatments with virtual patients in its integrated clinical trial simulation platform, Jinkō®.
NOVA is headquartered in Lyon, France and has a team of around 30 scientists, engineers & clinicians who work at the interface of biology, pharmacology, mathematics & computer science.
For more information, please visit https://www.novadiscovery.com
Novadiscovery inks new clinical simulation collaboration with Takeda
Mar. 26, 2021 8:12 AM ET
Takeda Pharmaceutical Company Limited (TAK)
By: Aakash Babu, SA News Editor
- Takeda Pharmaceutical Company (NYSE:TAK) and leading health tech company Novadiscovery have entered into a new collaboration aimed at incorporating clinical simulation technology on virtual patients into Takeda France’s access strategy.
- https://seekingalpha.com/news/3676726-novadiscovery-inks-new-clinical-simulation-collaboration-with-takeda
- https://seekingalpha.com/symbol/TAK
Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance
Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance
Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance
Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance
- EVOTEC LEVERAGES ITS PROPRIETARY SMALL MOLECULE RNA TARGETING PLATFORM AGAINST MULTIPLE RNA TARGETS ACROSS TAKEDA’S KEY INDICATIONS
- EVOTEC RECEIVES RESEARCH FUNDING AND IS ELIGIBLE FOR SUCCESS-BASED MILESTONES AND TIERED ROYALTIES
Hamburg, Germany, 22 March 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has entered into a multi-RNA target alliance with Takeda Pharmaceutical Company Limited (“Takeda”) with the goal to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches.
Evotec and Takeda will jointly identify and develop small molecules targeting a range of RNA targets aligned with Takeda’s research and development areas. The collaboration will leverage Evotec’s extensive RNA targeting platform to optimally identify promising RNA sequences to target with small molecule ligands that can be developed into potentially first-in-class therapeutics.
Under the terms of the agreement, Evotec will receive significant research funding and will be eligible to receive discovery, pre-clinical, clinical, commercial and sales milestone payments of up to US$ 160 m per programme. Additionally, Evotec is entitled to tiered royalties on net sales of any products resulting from the collaboration.
About Evotec’s RNA platform
The structure-based recognition of RNA tertiary structures by RNA-targeted small molecules (“rSM”) provides an alternative to sequence-based approaches, such as antisense oligonucleotides (“ASOs”). rSM approaches enable novel therapeutic potential by allowing to target highly conserved parts of RNA, creating pathways in cases where the encoded protein cannot be targeted conventionally, and unlocking the largely unexplored field of non-coding RNAs, which can also be disease drivers.
Evotec’s proprietary RNA targeting platform is specifically designed to
- identify RNA tertiary structural elements where rSM are able to bind with sufficient selectivity and affinity,
- discover and develop suitable rSM binders that potentially deliver orally available drugs, and
- identify and deliver proof-of-target engagement for disease-relevant RNA structures, allowing biologically active rSM binders.
Evotec’s cutting-edge RNA small molecule platform builds on the well-established drug discovery routes within Evotec and combines them with novel, highly innovative technologies such as third generation sequencing, sequencing-based structure elucidation of RNA molecules, which constitute a first-class expertise in this area.
For more information, visit www.takeda.com.
Evotec, Takeda form strategic RNA targeting alliance
Mar. 22, 2021 6:43 AM ET
By: Jignesh Mehta, SA News Editor
- Evotec SE (OTCPK:EVOTF) has entered into a multi-RNA target alliance with Takeda Pharmaceutical Company (NYSE:TAK) to discover and develop RNA targeting small molecule therapeutics for desirable targets that are difficult to address via conventional approaches.
https://seekingalpha.com/news/3674655-evotec-takeda-inks-strategic-rna-targeting-alliance
https://seekingalpha.com/symbol/EVOTF
https://seekingalpha.com/symbol/TAK
Enlivex enters Allocetra research collaboration with Yale Cancer Center
Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Ger
03/22/2021
Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra™ in Combination with Immune Checkpoint Inhibitors
Collaboration aims to evaluate the potential of Allocetra™ in combination with immune-checkpoint inhibitors in solid cancers that do not respond to stand-alone checkpoint inhibitor therapies.
Nes Ziona, Israel, March 22, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, together with Yale Cancer Center, a National Cancer Institute-designated comprehensive cancer center, today announced a research collaboration for the assessment of the potential of Allocetra™ to enhance the activity of checkpoint inhibitors in solid tumors. Allocetra™ is a macrophage-reprogramming immunotherapy product candidate currently in clinical development by Enlivex, as, among other things, a potential therapy in combination with approved immune checkpoint inhibitors for hard-to-treat solid tumors.
Under the strategic collaboration, the parties intend to develop and execute pre-clinical programs to investigate the potential synergies between Allocetra™ and commercially-approved checkpoint inhibitor therapies for select solid cancers.
The Principal Investigator for this collaboration is Dr. Vish Muthusamy, PhD, Director of the Yale Center for Precision Cancer Modeling. Dr. Muthusamy is a cancer biologist with expertise in preclinical investigation of candidate cancer therapies. His center has developed in vivo tumor models to investigate pharmacological evaluation of drugs. Recently, Dr. Muthusamy worked in close collaboration several academic investigators and pharmaceutical companies to develop cancer therapeutics that are in various stages of clinical development. The collaboration's scientific advisor is Dr. Marcus W. Bosenberg, MD, PhD, Co-Leader of the Genomics, Genetics and Epigenetics Program at Yale Cancer Center. On behalf of the Yale team, Dr. Bosenberg said "At Yale we have been interested in trying to understand the process of macrophage reprogramming for some time, and we are excited about studying the effects of Allocetra™ in potentially recruiting anti-tumor macrophages in the tumor environment and characterize the effects."
Dror Mevorach, M.D., Chief Medical Officer of Enlivex, commented, "We are excited to collaborate with the distinguished research and clinical teams at Yale. Allocetra™ may have a rebalancing effect on the typically immunosuppressive tumor microenvironment, potentially by facilitating the conversion of pro-tumor macrophage populations to anti-tumor populations. Together, we plan to investigate the potential of AllocetraTM to synergistically combine with commercially available checkpoint inhibitors for the treatment of solid tumors."
Oren Hershkovitz, Ph.D., CEO of Enlivex, stated, "We believe the researchers and clinicians at Yale are world-class and ideal partners as we work to realize Allocetra's potential. We are pleased to formulate a strategic collaboration with Yale for the development of Allocetra™ as a potentially key component of combination therapies for solid tumors."
Allocetra™ is currently in clinical development for acute life-threatening immune-mediated diseases, such as sepsis and COVID-19. Enlivex recently reported positive top-line results in 21 patients from Phase Ib and Phase II investigator-initiated trials in COVID-19 patients in severe/critical condition. The Company has also previously reported positive results from a Phase Ib investigator-initiated trial in 10 sepsis patients and plans to initiate a controlled, randomized, Phase IIb study in sepsis during the first quarter of 2021.
About Yale Cancer Center
Yale Cancer Center (YCC) is one of only 51 National Cancer Institute-designated comprehensive cancer centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Comprehensive cancer centers play a vital role in the advancement of the NCI's goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.
ABOUT ALLOCETRATM
Enlivex is developing AllocetraTM as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as "unmet medical needs," as a stand-alone therapy or in combination with leading therapeutic agents.
ABOUT ENLIVEX
Enlivex is a clinical stage immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions.
For more information, visit http://www.enlivex.com.
Enlivex enters Allocetra research collaboration with Yale Cancer Center
Mar. 22, 2021 8:35 AM ET
Enlivex Therapeutics Ltd. (ENLV)
By: Aakash Babu, SA News Editor
- Enlivex Therapeutics (NASDAQ:ENLV) announces a research collaboration with Yale Cancer Center for the assessment of the potential of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors.
https://www.yalecancercenter.org/
Allocetra™ Macrophage reprogramming
https://enlivex.com/allocetra/
https://seekingalpha.com/symbol/ENLV
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Ger
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Ger
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Ger
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate XL092 and Avelumab in Various Forms of Locally Advanced or Metastatic Urothelial Carcinoma
– New expansion cohorts to be added to ongoing STELLAR-001 trial following dose-escalation phase –
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 18, 2021-- Exelixis, Inc. (Nasdaq:EXEL) today announced a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer for the ongoing phase 1b dose escalation study STELLAR-001 (previously called “XL092-001”), adding three new cohorts that will evaluate the safety and tolerability of XL092, Exelixis’ novel next generation tyrosine kinase inhibitor (TKI), in combination with avelumab (BAVENCIO®), an anti-PD-L1 immune checkpoint inhibitor (ICI), in patients with locally advanced or metastatic urothelial carcinoma (UC). Avelumab is being co-developed and co-commercialized by Merck KGaA, Darmstadt, Germany and Pfizer. Exelixis is sponsoring the STELLAR-001 clinical trial, and Merck KGaA, Darmstadt, Germany and Pfizer will provide avelumab for use in the trial.
“We are pleased to collaborate with Merck KGaA, Darmstadt, Germany and Pfizer to study the potential of XL092 in combination with avelumab as part of the broad development program evaluating our novel next generation tyrosine kinase inhibitor across a wide variety of cancers,” said Gisela Schwab, M.D., President, Product Development and Medical Affairs and Chief Medical Officer, Exelixis. “Although several therapies are now available to treat bladder cancers, the prognosis for patients with advanced disease remains poor and more options are needed. Evaluating how XL092 may positively impact care when paired with immunotherapy is central to our goal of improving therapeutic outcomes for patients with this and other difficult-to-treat cancers.”
Based on the dose-escalation results, the trial has the potential to enroll up to three expansion cohorts evaluating XL092 in combination with avelumab in metastatic UC, including as maintenance therapy, in patients who have progressed following treatment with an ICI, and in patients previously treated with platinum-containing chemotherapy.
XL092 is an investigational, next-generation oral TKI that targets VEGF receptors, MET, AXL, MER and other kinases implicated in the growth and spread of cancer. Preclinical findings presented at the 32nd EORTC-NCI-AACR Symposium in October 2020 showed that XL092 in combination with an ICI was more efficacious than either XL092 or anti-PD1 alone. Single-agent avelumab is the only ICI approved in the U.S. for maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-based chemotherapy.
More information about this trial is available at ClinicalTrials.gov.
About XL092
XL092 is a next-generation oral TKI that targets VEGF receptors, MET, AXL, MER and other kinases implicated in cancer’s growth and spread. In designing XL092, Exelixis sought to build upon the experience and target profile of cabozantinib, the company’s flagship medicine, while improving key characteristics, including clinical half-life. XL092 is the first internally discovered Exelixis compound to enter the clinic following the company’s reinitiation of drug discovery activities.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210318005146/en/
Pfizer, Merck KGaA and Exelixis to collaborate in bladder cancer trial
Mar. 18, 2021 8:32 AM ET
By: Dulan Lokuwithana, SA News Editor5 Comments
- Exelixis (NASDAQ:EXEL) announced a collaboration with Pfizer (NYSE:PFE) and Merck KGaA (OTCPK:MKGAF) in an ongoing phase 1b dose-escalation study, STELLAR-001 for XL092, the company’s oral tyrosine kinase inhibitor targeting cancer growth and spread.
https://seekingalpha.com/symbol/EXEL
Exelixis Inc (NASDAQ: EXEL) has announced a clinical trial collaboration and supply agreement with Germany's Merck KGaA and Pfizer Inc (NYSE: PFE) for the ongoing Phase 1b dose-escalation study STELLAR-001.
https://seekingalpha.com/symbol/MKGAF
https://seekingalpha.com/symbol/PFE
Gilead and Novo Nordisk Expand NASH Clinical Collaboration
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Ger
illumina inks deal with Geneseeq for in-vitro diagnostic NGS kit in china
March 18, 2021
Gilead and Novo Nordisk Expand NASH Clinical Collaboration
– Triple Combination Regimen to be Investigated in New Phase 2b Study in NASH Patients with Cirrhosis –
FOSTER CITY, Calif. & BAGSVÆRD, Denmark--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Novo Nordisk A/S (Nasdaq Copenhagen: NOVO B) today announced that the companies have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210318005315/en/
The companies will conduct a Phase 2b double-blind, placebo-controlled study to investigate the safety and efficacy of Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, and a fixed-dose combination of Gilead’s investigational FXR agonist cilofexor and investigational ACC inhibitor firsocostat, alone and in combination in people with compensated cirrhosis (F4) due to NASH. The four-arm study in approximately 440 patients will evaluate the treatments’ impact on liver fibrosis improvement and NASH resolution and will begin recruitment in the second half of 2021.
For more information, visit novonordisk.com,
Gilead and Novo Nordisk expand collaboration in NASH therapeutics
Mar. 18, 2021 7:02 AM ET
By: Dulan Lokuwithana, SA News Editor4 Comments
- Gilead Sciences (NASDAQ:GILD) and Novo Nordisk (NYSE:NVO) have announced an expansion of their clinical collaboration in non-alcoholic steatohepatitis (“NASH”).
https://seekingalpha.com/symbol/GILD
https://seekingalpha.com/symbol/NVO
illumina inks deal with Geneseeq for in-vitro diagnostic NGS kit in china
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Ger
illumina inks deal with Geneseeq for in-vitro diagnostic NGS kit in china
Geneseeq Inks Deal with Illumina to Develop and Commercialize Comprehensive Cancer In-vitro Diagnostic NGS Kit in China
Tue March 16, 2021 10:00 AM|PR Newswire|About: ILMN
TORONTO, March 16, 2021 /PRNewswire/ - Next-generation sequencing (NGS)-based precision oncology provider Geneseeq Technology Inc. ("Geneseeq"), will collaborate with Illumina, Inc. (ILMN) ("Illumina") to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer, using Illumina's NextSeq™ 550Dx sequencing platform. The companies will work together to promote the use and application of world leading Next-Generation-Sequencing technology to enhance standards-of-care for Chinese patients.
Geneseeq's comprehensive genomic profiling panel, GeneseeqPrime®, analyzes genomic alterations in 425 cancer-related genes and assesses key biomarkers, such as tumor mutation burden (TMB) and microsatellite instability (MSI). This pan-cancer panel screens for actionable clinical next steps to therapy by providing valuable insight into key oncogenic genes and drug resistance mechanisms. In 2020, Geneseeq's TMB Testing Kit in non-small cell lung cancer (NSCLC) became the first comprehensive NGS panel entered into the Breakthrough Medical Devices Program of Chinese National Medical Products Administration (NMPA). This is the second time that the two companies joined forces to accelerate clinical availability in precision cancer care. In 2018, the two companies collaborated on the NMPA approval of the IVD kit, Essencare®(EGFR/ALK/ROS1/BRAF/KRAS/HER2 mutation testing kit, Reversible terminator sequencing) for NSCLC.
For more information, please visit their website
To learn more, visit www.illumina.com
View original ontent:
SOURCE Geneseeq Technology Inc.
illumina inks deal with Geneseeq for in-vitro diagnostic NGS kit in china
Mar. 16, 2021 11:49 AM ET
By: Aakash Babu, SA News Editor
- Illumina (ILMN +0.5%) signs deal with precision oncology provider Geneseeq Technology to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer, using Illumina's NextSeq 550Dx sequencing platform in China.
- https://seekingalpha.com/news/3673204-illumina-inks-deal-with-geneseeq-for-in-vitro-diagnostic-ngs-kit-in-china
- https://seekingalpha.com/symbol/ILMN
Merck and Gilead announce partnership for long-acting HIV treatments
Merck and Gilead announce partnership for long-acting HIV treatments
Merck and Gilead announce partnership for long-acting HIV treatments
March 15, 2021
Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV
– Collaboration to Focus on Oral and Injectable Formulations of Lenacapavir and Islatravir –
– Agreement Brings Together Potentially Complementary Medicines in Late-Stage Development with the Goal to Provide Innovative, Long-Acting Treatments in HIV –
FOSTER CITY, Calif. & KENILWORTH, N.J.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that they have entered into an agreement to co-develop and co-commercialize long-acting treatments in HIV that combine Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir,into a two-drug regimen with the potential to provide new, meaningful treatment options for people living with HIV. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210315005226/en/
Islatravir and lenacapavir are both potentially first-in-class medicines in late-stage clinical trials, with significant clinical data generated to date. Both medicines have long half-lives and have demonstrated activity at low dosages in clinical studies, which support development as an investigational combination regimen with long-acting formulations, both oral and injectable.
The first clinical studies of the oral combination are expected to begin in the second half of 2021. Under the terms of the agreement, Gilead and Merck will work as partners, sharing operational responsibilities, as well as development, commercialization and marketing costs, and any future revenues.
Merck and Gilead seek to build on their legacies of transforming HIV care by focusing on long-acting therapies, which may represent a meaningful innovation in HIV drug development. While daily, single tablet regimens are available for people living with HIV, options that would allow for less frequent, oral dosing or infrequent injections rather than daily dosing have the potential to address preference considerations, as well as issues associated with adherence and privacy.
Terms of the Collaboration
Under the terms of the agreement, Gilead and Merck will co-develop and co-commercialize long-acting products to treat people living with HIV that combine Gilead’s proprietary investigational capsid inhibitor, lenacapavir, and Merck’s proprietary investigational nucleoside reverse transcriptase translocation inhibitor, islatravir. The collaboration will initially focus on long-acting oral formulations and long-acting injectable formulations of these combination products, with other formulations potentially added to the collaboration as mutually agreed.
About Islatravir (MK-8591)
Islatravir (formerly MK-8591) is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) that exhibits both translocation inhibition (which prevents nucleotide binding and incorporation to the DNA chain, resulting in immediate chain termination) and delayed chain termination (which prevents nucleotide incorporation even in the event of translocation). Islatravir is currently being evaluated for the treatment of HIV-1 infection in combination with other antiretrovirals, including the ILLUMINATE clinical trials program for oral, once-daily treatment. Islatravir is also being studied for preexposure prophylaxis (PrEP) of HIV-1 infection as a single agent across a variety of formulations, including the IMPOWER clinical trials evaluating an oral once-monthly regimen. In 2012, Merck licensed islatravir (4’-ethynyl-2-fluoro-2’-deoxyadenosine or EFdA) from the Yamasa Corporation based in Choshi, Japan.
About Lenacapavir
Lenacapavir is a novel investigational capsid inhibitor that interrupts the activity of HIV capsid, a protein that surrounds and protects the virus’ genetic material and essential enzymes. In in vitro studies, lenacapavir interrupts multiple distinct stages of the viral lifecycle, potentially preventing the virus from becoming infectious and gaining access to uninfected cells.
The safety, efficacy and dosing of lenacapavir are being evaluated in multiple ongoing clinical studies. Data presented at AIDS 2020 from the ongoing Phase 1 study support subcutaneous every six-month administration of lenacapavir for both HIV treatment and prevention studies. During IDWeek 2020, the company announced it would be evaluating the use of lenacapavir among cisgender women as an injectable PrEP option administered every six months. An additional lenacapavir for PrEP study in men who have sex with men and persons of trans experience is planned. Both studies are expected to begin in 2021.
For more information about Gilead, please visit the company’s website at www.gilead.com.
For more information, visit www.merck.com
Merck and Gilead announce partnership for long-acting HIV treatments
Mar. 15, 2021 10:50 AM ET
By: Dulan Lokuwithana, SA News Editor15 Comments
- Merck (MRK +1.2%) has partnered with Gilead Sciences (GILD +0.8%) to co-develop and co-commercialize long-acting treatments targeting people living with HIV.
- https://seekingalpha.com/news/3672687-merck-and-gilead-partnership-for-long-acting-hiv-treatments
- https://seekingalpha.com/symbol/GILD
- https://seekingalpha.com/symbol/MRK
Lilly and Biolojic Design Announce Research Collaboration
Merck and Gilead announce partnership for long-acting HIV treatments
Merck and Gilead announce partnership for long-acting HIV treatments
Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes
March 8, 2021
Biolojic is eligible to receive up to $121 million, consisting of potential milestones and a promissory note, as well as tiered royalties
INDIANAPOLIS and TEL AVIV, March 8, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Biolojic Design Ltd. ("Biolojic"), a biotechnology company that computationally designs functional antibodies, today announced a research collaboration and license agreement that will leverage Biolojic's AI-based multibody platform to discover and develop a potential novel antibody-based therapy for the treatment of diabetes.
Under the terms of the agreement, Lilly will pay research fees associated with the collaboration and additionally, Biolojic is eligible to receive up to a total of $121 million, consisting of potential development and commercialization milestones and a promissory note that may be convertible into Biolojic equity at a future date. Biolojic is also eligible to receive tiered royalties in the low- to mid-single digits on product sales should Lilly successfully commercialize a therapy from the collaboration.
To learn more, please visit www.biolojic.com.
To learn more about Lilly, please visit us at www.lilly.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-and-biolojic-design-announce-research-collaboration-to-discover-and-develop-antibody-therapies-for-diabetes-301242715.html
Lilly to collaborate with Biolojic Design to develop diabetes antibody therapies
Mar. 08, 2021 5:20 PM ET
By: Jonathan M Block, SA News Editor
- Eli Lilly and Company (NYSE:LLY) has inked a research collaboration agreement with privately held Biolojic Design to leverage the latter's artificial intelligence-based multibody platform to discover novel antibody therapies for diabetes.
https://seekingalpha.com/symbol/LLY
Exelixis Enters into Exclusive License Agreement with WuXi Biologics
Merck and Gilead announce partnership for long-acting HIV treatments
Exelixis Enters into Exclusive License Agreement with WuXi Biologics
Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline
– Exelixis has exclusive license to panel of monoclonal antibodies against an undisclosed oncology target for biologics applications, leveraging WuXi Biologics integrated technology platforms –
– In addition to a modest upfront payment, WuXi Biologics is eligible for potential milestones and royalties on net sales of potential products –
ALAMEDA, Calif. & SHANGHAI--(BUSINESS WIRE)--Mar. 8, 2021-- Exelixis, Inc. (Nasdaq: EXEL) and WuXi Biologics (“WuXi Bio”) (2269.HK) today announced the companies have entered into an exclusive license agreement to support the continued expansion of Exelixis’ oncology biologics pipeline. The agreement is the latest in a series of biologics-focused transactions for Exelixis as the company builds out its pipeline behind CABOMETYX® (cabozantinib), its flagship product and global oncology franchise, which received its fourth approval from the U.S. Food and Drug Administration in January.
This press release features multimedia.
View the full release here: https://www.businesswire.com/news/home/20210308005465/en/
Under the terms of the agreement, Exelixis will make a modest upfront payment to WuXi Bio in exchange for an exclusive license to a panel of monoclonal antibodies to a preclinically validated target, discovered based on WuXi Bio’s integrated technology platforms, for the development of antibody-drug conjugate, bispecific, and certain other novel tumor-targeting biologics applications. WuXi Bio will be eligible for development and commercialization milestones, as well as tiered royalties on net sales of any potential products commercialized from the panel.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
For more information about Exelixis, please visit www.exelixis.com
Exelixis enters WuXi Biologics deal in oncology pipeline push
Mar. 08, 2021 11:36 AM ET Exelixis, Inc. (EXEL)
By: Aakash Babu, SA News Editor
Exelixis (EXEL -0.7%) and WuXi Biologics tie up in an exclusive license agreement to support the continued expansion of Exelixis’ oncology biologics pipeline.
https://seekingalpha.com/news/3670323-exelixis-enters-wuxi-biologics-deal-in-oncology-pipeline-push
https://seekingalpha.com/symbol/EXEL
Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash
BIOGEN TO BUILD A NEW GENE THERAPY MANUFACTURING FACILITY IN RESEARCH TRIANGLE PARK, NORTH CAROLINA
Exelixis Enters into Exclusive License Agreement with WuXi Biologics
Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash
Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality Worldwide
Bemarituzumab is a Strong Strategic Fit With Amgen's Innovative Oncology Portfolio
Amgen to Host Investor Call at 10:30 a.m. EST
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., March 4, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of approximately $1.9 billion. This acquisition adds Five Prime's innovative pipeline to Amgen's leading oncology portfolio.
About FGFR2b
The fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) pathway is implicated in the development and growth of cancer cells. FGFR2b is a splice variant of FGFR2 which can be found in tumors of epithelial origin. Data from the FIGHT trial suggests that approximately 30 percent of patients with non-HER2 positive gastroesophageal cancers overexpress FGFR2b.1 FGFR2b has also been shown to be overexpressed in numerous other cancers, including lung, breast, ovarian and other cancers.
About Bemarituzumab
Bemarituzumab (anti-FGFR2b) is a first-in-class targeted antibody that blocks fibroblast growth factors (FGFs) from binding and activating FGFR2b, inhibiting several downstream pro-tumor signaling pathways and potentially slowing cancer progression. Five Prime Therapeutics granted an exclusive license to Zai Lab Limited to develop and commercialize bemarituzumab in Greater China, and Zai Lab collaborated with Five Prime Therapeutics on the Phase 2 FIGHT trial in Greater China.
For more information, visit www.amgen.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/amgen-to-acquire-five-prime-therapeutics-for-1-9-billion-in-cash-301240358.html
SOURCE Amgen
Amgen to acquire Five Prime Therapeutics for $1.9B
Mar. 04, 2021 9:00 AM ET
By: Mamta Mayani, SA News Editor2 Comments
- Amgen (NASDAQ:AMGN) and Five Prime Therapeutics (NASDAQ:FPRX) ink merger agreement under which, AMGN will acquire Five Prime for $38.00/share in cash, representing an equity value of ~$1.9B. This acquisition adds Five Prime's innovative pipeline to Amgen's oncology portfolio with a promising late-stage candidate, bemarituzumab.
https://seekingalpha.com/news/3669372-amgen-to-acquire-five-prime-therapeutics-for-19b
https://seekingalpha.com/symbol/FPRX
https://seekingalpha.com/symbol/AMGN
ARCALYST®(rilonacept)
BIOGEN TO BUILD A NEW GENE THERAPY MANUFACTURING FACILITY IN RESEARCH TRIANGLE PARK, NORTH CAROLINA
BIOGEN TO BUILD A NEW GENE THERAPY MANUFACTURING FACILITY IN RESEARCH TRIANGLE PARK, NORTH CAROLINA
Regeneron and Kiniksa sign commercial supply agreement for Rilonacept
Mar. 03, 2021 5:07 PM ET
Kiniksa Pharmaceuticals, Ltd. (KNSA)
By: Dulan Lokuwithana, SA News Editor1 Comment
- Kiniksa Pharmaceuticals (NASDAQ:KNSA) has announced a commercial supply agreement with Regeneron (NASDAQ:REGN) giving the latter the exclusive right to manufacture and supply rilonacept for Kiniksa’s U.K. subsidiary.
Rilonacept
ARCALYST®
(rilonacept) INJECTION
Indication
ARCALYST® (rilonacept) Injection for Subcutaneous Use is used to treat adults and children 12 years of age and older with Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).
Rilonacept
https://www.kiniksa.com/our-pipeline/rilonacept/
https://seekingalpha.com/symbol/REGN
https://seekingalpha.com/symbol/KNSA
BIOGEN TO BUILD A NEW GENE THERAPY MANUFACTURING FACILITY IN RESEARCH TRIANGLE PARK, NORTH CAROLINA
BIOGEN TO BUILD A NEW GENE THERAPY MANUFACTURING FACILITY IN RESEARCH TRIANGLE PARK, NORTH CAROLINA
BIOGEN TO BUILD A NEW GENE THERAPY MANUFACTURING FACILITY IN RESEARCH TRIANGLE PARK, NORTH CAROLINA
BIOGEN ANNOUNCES PLANS TO BUILD A NEW, STATE-OF-THE-ART GENE THERAPY MANUFACTURING FACILITY IN RESEARCH TRIANGLE PARK, NORTH CAROLINA
March 4, 2021 at 7:48 AM EST
- The innovative and scalable gene therapy manufacturing facility will support Biogen’s plan to advance its gene therapy portfolio
- The new facility is expected to employ approximately 90 people and to be operational by 2023
CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced its plans to build a new gene therapy manufacturing facility at its Research Triangle Park (RTP) manufacturing campuses in North Carolina to support its growing gene therapy pipeline across multiple therapeutic areas.
As pioneers in neuroscience, Biogen is pursuing multiple modalities with the aim of bringing life-saving medicines to those who suffer from serious neurological and neurodegenerative diseases. With this new facility, Biogen is investing in robust and scalable gene therapy manufacturing with the goal of ensuring reliable supply to patients worldwide. Gene therapy is an emerging therapeutic modality that may be suitable for a growing list of genetically validated targets in neuroscience.
“We plan to build differentiated, sustainable and advanced manufacturing capabilities to support our gene therapy programs and collaborations,” said Nicole Murphy, Senior Vice President, Global Manufacturing and Technical Operations. “This additional investment underscores our commitment to RTP and our mission to deliver a reliable supply of high-quality medicines to the patients we serve. We are poised with a diverse workforce that is passionate about making a difference in the lives of patients and we look forward to welcoming new colleagues from the community to join us in that mission.”
Through the new facility, Biogen aims to continue its investment in North Carolina and expand its existing operations and combined workforce of approximately 1,900 employees at both campuses in RTP. Biogen anticipates that the new facility will create approximately 90 new jobs, with an estimated total investment of approximately $200 million. Biogen selected RTP for this new facility given the region’s diverse pool of talent and the company’s 26-year track record of attracting highly qualified and passionate employees in North Carolina. Biogen’s priority is to continue to foster and enable a diverse and inclusive workforce – representing age, gender, sexual identity, race, ethnicity, Veterans, and people with disabilities – that reflects the communities where we operate and the patients who we serve.
The site will be 175,000 square feet and designed in compliance with the most advanced sustainability standards regarding energy use, waste management and water consumption.
Biogen to build new gene therapy facility
Mar. 04, 2021 8:18 AM ET
Biogen Inc. (BIIB)By: Aakash Babu, SA News Editor
- Biogen (NASDAQ:BIIB) announces plans to build a new gene therapy manufacturing facility at its Research Triangle Park (RTP) manufacturing campuses in North Carolina to support its growing gene therapy pipeline across multiple therapeutic areas.
https://seekingalpha.com/news/3669331-biogen-to-build-new-gene-therapy-facility
https://seekingalpha.com/symbol/BIIB
BiotechVortex™
Enlivex and Mount Sinai Health System Announce Research Collaboration
Enlivex and Mount Sinai Health System Announce Research Collaboration
Enlivex and Mount Sinai Health System Announce Research Collaboration
03/01/2021Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors
-- Collaboration aims to evaluate the potential of Allocetra™ in combination with immune-checkpoint inhibitors in solid cancer patients that do not respond to stand-alone checkpoint inhibitor therapies --
Nes Ziona, Israel, March 01, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, and Mount Sinai Health System, one of the world's leading academic health systems, today announced a new research collaboration for the development of clinical strategies for Allocetra™ with checkpoint inhibitors. Allocetra™ is a macrophage-reprogramming immunotherapy product candidate currently in clinical development by Enlivex for the potential treatment of life-threatening immune-mediated diseases.
Under the strategic collaboration agreement, the parties have agreed to develop and execute a pre-clinical program to investigate the potential synergies between Allocetra™ and commercially approved checkpoint inhibitor therapies for select solid cancers.
ABOUT ALLOCETRATM
AllocetraTM is a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as "unmet medical needs", as a stand-alone therapy or in combination with leading therapeutic agents.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.
Allocetra™ Macrophage reprogramming
https://enlivex.com/allocetra/
Enlivex and Mount Sinai Health System announce research collaboration deal
Mar. 01, 2021 8:10 AM ET
Enlivex Therapeutics Ltd. (ENLV)
By: Aakash Babu, SA News Editor
- Enlivex Therapeutics (NASDAQ:ENLV) and New York City's largest academic medical system Mount Sinai Health System announce a new research collaboration for the development of clinical strategies for Allocetra with checkpoint inhibitors.
https://seekingalpha.com/symbol/ENLV
fixed doses of COM701 and Opdivo®
Enlivex and Mount Sinai Health System Announce Research Collaboration
Enlivex and Mount Sinai Health System Announce Research Collaboration
Compugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb with Phase 1b Combination Study of COM701 with Opdivo®
February 22, 2021Cohort expansion study expected to commence in the second quarter of 2021
HOLON, Israel, Feb. 22, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the expansion of its clinical collaboration agreement with Bristol Myers Squibb. Under the amended agreement, Bristol Myers Squibb will supply Opdivo® (nivolumab), its PD-1 inhibitor, for Compugen's Phase 1b cohort expansion study designed to assess COM701, Compugen's first-in-class anti-PVRIG antibody, in combination with Opdivo® in selected cancer indications. Study initiation is expected in the second quarter of 2021.
For additional information, please visit Compugen's corporate website at www.cgen.com.
View original content
SOURCE Compugen Ltd.
fixed doses of COM701 and Opdivo®
Dr. Cohen-Dayag continued, "Bristol Myers Squibb continues to be a valued partner for our COM701 clinical program as we advance the immunotherapy treatment landscape of patients with cancer."
Under the terms of the amendment, Bristol Myers Squibb will continue to supply Opdivo® to the Compugen-sponsored study. The Phase 1b study, a part of Compugen's COM701 monotherapy and combination therapy dose escalation and expansion program (NCT03667716), will examine fixed doses of COM701 and Opdivo®, as determined by Compugen's Phase 1a combination dose escalation study. Based on Compugen's translational analyses and preliminary antitumor activity in dose escalation, the study will enroll patients with ovarian, breast, endometrial and microsatellite-stable colorectal cancers.
Compugen expands deal with Bristol Myers for phase 1b COM701 combo study
Feb. 22, 2021 12:12 PM ET
By: Aakash Babu, SA News Editor
- Compugen (CGEN -5.3%) announces the expansion of its clinical collaboration agreement with Bristol Myers Squibb (BMY -0.1%) to supply blockbuster cancer treatment Opdivo (nivolumab), for Compugen's Phase 1b cohort expansion study to assess COM701, an anti-PVRIG antibody, in combination with Opdivo in selected cancer indications.
https://seekingalpha.com/symbol/CGEN
Compugen’s Triple Checkpoint Hypothesis
Enlivex and Mount Sinai Health System Announce Research Collaboration
Compugen’s Triple Checkpoint Hypothesis
Compugen’s Triple Checkpoint Hypothesis
•Jan 20, 2021 Compugen Ltd.
At Compugen, we believe that the PVRIG pathway we discovered is a potential paradigm shifting target to enhance patient responses to cancer immunotherapies and may provide new treatment options as monotherapy or in combination with other immune checkpoints to expand the reach of cancer immunotherapies to new patient populations. Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Compugen’s lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen’s antibody targeting TIGIT, is in a Phase 1 clinical study. Compugen’s therapeutic pipeline also includes early stage immuno-oncology programs focused largely on myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen’s corporate website at www.cgen.com.
Merck to Acquire Pandion Therapeutics
Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab)
Compugen’s Triple Checkpoint Hypothesis
Merck to Acquire Pandion Therapeutics
February 25, 2021 6:45 am EST
Acquisition Adds Pipeline of Candidates Targeting a Broad Range of Autoimmune Diseases
KENILWORTH, N.J & WATERTOWN, Mass.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pandion Therapeutics, Inc. (Nasdaq: PAND) today announced that the companies have entered into a definitive agreement, under which Merck, through a subsidiary, will acquire Pandion, a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, for $60 per share in cash. This represents an approximate total equity value of $1.85 billion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005318/en/
About PT101
PT101 is an engineered IL-2 mutein fused to a protein backbone designed to selectively activate and expand regulatory T cells for the treatment of autoimmune diseases. In autoimmune diseases, the immune system inappropriately attacks a host’s cells, and targeting Tregs could allow the immune system to regain control and return to homeostasis. PT101 has completed a Phase 1a clinical trial, which achieved its primary objective of safety and tolerability. In the trial, PT101 demonstrated proof of mechanism by selectively expanding Tregs in healthy volunteers.
For more information, please visit www.pandiontx.com
For more information, visit www.merck.com
Pandion is focused on developing therapeutics for a wide range of autoimmune and inflammatory indications.
https://pandiontx.com/pipeline/overview/
Merck to acquire Pandion for $2 billion
Feb. 25, 2021 7:09 AM ET
By: Dulan Lokuwithana, SA News Editor
- Merck (NYSE:MRK) has agreed to acquire Pandion Therapeutics (NASDAQ:PAND) for $60 per share in an all-cash deal valuing Pandion at $1.85B.
https://seekingalpha.com/news/3666246-merck-to-acquire-pandion-in-a-deal-valued-at-2-billion
https://seekingalpha.com/symbol/PAND
https://seekingalpha.com/symbol/MRK
RIPK1 Inhibitors
Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab)
Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab)
Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases
February 18, 2021 6:30am EST
- Lilly will obtain an exclusive worldwide license to Rigel's RIPK1 inhibitors, including Rigel's Phase 2-ready molecule R552, in all indications
- Rigel will receive an upfront cash payment of $125 million, with the potential for up to an additional $835 million in future development, regulatory, and commercial milestones
INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., Feb. 18, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases. Pursuant to the collaboration, Lilly will also lead all clinical development of brain penetrating RIPK1 inhibitors in central nervous system (CNS) diseases.
RIPK1 Inhibitors
Rigel's lead RIPK1 inhibitor, R552, has completed Phase 1 clinical trials and will begin Phase 2 clinical trials in 2021 as part of the collaboration. Rigel also has ongoing pre-clinical activities with its lead CNS penetrant RIPK1 inhibitor candidates.
Under the terms of the agreement, Lilly will pay an upfront cash payment to Rigel of $125 million. Rigel may also be eligible to receive up to $835 million in potential development, regulatory, and commercial milestone payments, as well as tiered royalties ranging from the mid-single digit to high-teens that will vary depending upon Rigel's clinical development investment. Lilly and Rigel will co-develop R552 at specified contribution levels. Lilly will be responsible for all costs of global commercialization for R552, and Rigel will have the right to co-commercialize R552 in the U.S. Lilly will be solely responsible for all clinical development and commercialization of brain penetrating RIPK1 inhibitors in CNS indications.
RIPK1 is a critical signaling protein implicated in a broad range of key inflammatory cellular processes including necroptosis, a type of regulated cell death, and cytokine production. In necroptosis, cells rupture leading to the dispersion of cell contents which can trigger an immune response and enhance inflammation. Inhibiting RIPK1 may be a new approach to treating various autoimmune, inflammatory, and neurodegenerative disorders. In pre-clinical studies, Rigel's R552 demonstrated prevention of joint and skin inflammation in a RIPK1-mediated murine model of inflammation and tissue damage.
To learn more about Rigel, please visit us at www.rigel.com.
To learn more about Lilly, please visit us at www.lilly.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-and-rigel-enter-strategic-collaboration-to-develop-ripk1-inhibitors-for-the-potential-treatment-of-immunological-and-neurodegenerative-diseases-301230502.html
SOURCE Eli Lilly and Company; Rigel Pharmaceuticals
Released February 18, 2021
Rigel shares surge 41% on RIPK1 inhibitors deal with Eli Lilly
Feb. 18, 2021 6:47 AM ET
Rigel Pharmaceuticals, Inc. (RIGL)
By: Mamta Mayani, SA News Editor7 Comments
- Rigel Pharmaceuticals (NASDAQ:RIGL) soars 41% premarket after announcing a global license agreement and strategic collaboration Eli Lilly (NYSE:LLY) to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases.
https://seekingalpha.com/news/3663357-eli-lilly-rigel-team-up-to-develop-ripk1-inhibitors
https://seekingalpha.com/symbol/LLY
https://seekingalpha.com/symbol/RIGL
Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab)
Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab)
Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab)
Feb 17, 2021PDF Version Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN)
SAN FRANCISCO, Feb. 17, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada) for a Phase 2/3 study of bempegaldesleukin (NKTR-214, BEMPEG), Nektar's investigational IL-2 pathway agent, in combination with Merck's KEYTRUDA® (pembrolizumab) for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck (SCCHN) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1). The study is planned to start in the second half of 2021.
Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab)
"We are excited to advance the combination of BEMPEG plus KEYTRUDA to a Phase 2/3 study in first-line squamous cell carcinoma of the head and neck," said Jonathan Zalevsky, PhD, Chief R&D Officer at Nektar. "Earlier studies of BEMPEG in combination with immune checkpoint inhibitors, also known as ICIs, evaluated in patients with immune-sensitive cancers have shown the potential to increase and deepen treatment responses as compared to historical rates for ICIs alone. This collaboration with Merck will enable us to further explore the combination of BEMPEG with the leading checkpoint inhibitor therapy in the setting of advanced head and neck cancer."
Under the terms of the agreement, Nektar will conduct the Phase 2/3 study, which is expected to enroll 500 patients with metastatic or recurrent SCCHN with PD-L1 expressing tumors. Patients will be randomized to receive either the combination of BEMPEG plus pembrolizumab or pembrolizumab alone. The Phase 2 portion of the study will include an interim analysis of overall response rate (ORR) after the first 200 patients enrolled have a minimum follow up of 4 months. If the ORR passes a prespecified futility boundary, the study will continue, and the remaining 300 patients will be enrolled to the Phase 3 portion of the study. The primary endpoints of the trial are ORR and overall survival (OS); progression free survival (PFS) is a secondary endpoint.
Bempegaldesleukin (NKTR-214)
https://www.nektar.com/pipeline/rd-pipeline/nktr-214
Nektar and Merck team up in mid-stage cancer combo study
Feb. 17, 2021 10:59 AM ET Nektar Therapeutics (NKTR) By: Aakash Babu, SA News Editor2 Comments
- Nektar Therapeutics (NKTR +11.8%) has entered into a clinical trial collaboration and supply agreement with Merck (MRK +1.9%) for a Phase 2/3 study of Nektar's bempegaldesleukin in combination with Merck's blockbuster cancer drug KEYTRUDA for first-line treatment of certain patients with squamous cell carcinoma.
https://seekingalpha.com/news/3662897-nektar-and-merck-team-up-in-mid-stage-cancer-combo-study
https://seekingalpha.com/symbol/NKTR
GSK and Vir Biotechnology Expand Coronavirus Collaboration
BMY & Rockefeller Uni = License Agreement - SARS-CoV-2 Neutralizing Monoclonal Antibody Combination
BMY & Rockefeller Uni = License Agreement - SARS-CoV-2 Neutralizing Monoclonal Antibody Combination
GSK and Vir Biotechnology Expand Coronavirus Collaboration to Advance New Therapeutics for Influenza and Other Respiratory Viruses
02/17/21 at 7:04 AM ESTPDF Version
– Companies applying their combined expertise in immunology and infectious diseases to accelerate the development of promising monoclonal antibody candidates for influenza –
– Functional genomics collaboration expanded to include respiratory viruses, Vir’s unique technology, and access to GSK’s small molecule compounds –
– Additional exploration of up to three other antibodies for pathogens
beyond influenza and coronaviruses –
– GSK is increasing its equity investment by $120 million and making an upfront
payment of $225 million –
LONDON and SAN FRANCISCO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced they have signed a binding agreement to expand their existing collaboration to include the research and development of new therapies for influenza and other respiratory viruses.
About Vir’s Antibody Platform
Vir has a robust method for capitalizing on unusually successful immune responses naturally occurring in people who are protected from, or have recovered from, infectious diseases. The platform is used to identify rare antibodies from survivors that have the potential to treat and prevent rapidly evolving and/or previously untreatable pathogens via direct pathogen neutralization and immune system stimulation. Vir engineers the fully human antibodies that it discovers to enhance their therapeutic potential. This platform has been used to identify and develop antibodies for pathogens including SARS-CoV-2, hepatitis B virus, influenza A, Ebola (mAb114, approved for use in the U.S. as EbangaTM and marketed by Ridgeback Therapeutics LP), malaria and others.
About VIR-2482
VIR-2482 is an investigational intramuscularly administered influenza A-neutralizing monoclonal antibody. In vitro, it has been shown to cover all major strains of influenza A that have arisen since the 1918 Spanish flu pandemic. VIR-2482 is designed as a universal prophylactic for influenza A. It has the potential to overcome the limitations of current flu vaccines and lead to meaningfully higher levels of protection due to its broad strain coverage and because it does not rely on an individual to create their own protective antibody response. VIR-2482 has been half-life engineered so that a single dose has the potential to last the entire flu season.
About VIR-7831 / GSK4182137
VIR-7831 is an investigational dual-action SARS-CoV-2 monoclonal antibody. Preclinical data suggest it has the potential to both block viral entry into healthy cells and clear infected cells. The antibody binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. VIR-7831 also has been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.
About VIR-7832 / GSK4182136
VIR-7832 is an investigational dual-action SARS-CoV-2 monoclonal antibody. Preclinical data suggest it has the potential to both block viral entry into healthy cells and an enhanced ability to clear infected cells. The antibody binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. VIR-7832 also has been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life. Importantly, VIR-7832 has also been engineered to potentially enhance virus-specific T cell function, which could help treat and/or prevent COVID-19 infection.
About the Vir and GSK Collaboration
In April 2020, Vir and GSK entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies are leveraging GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They are also applying their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.
For more information, please visit www.vir.bio.
For further information please visit www.gsk.com/about-us.
GSK, Vir Bio to advance new therapies for influenza and other respiratory viruses
Feb. 17, 2021 7:47 AM ETVir Biotechnology, Inc. (VIR)By: Mamta Mayani, SA News Editor
- Vir Biotechnology (NASDAQ:VIR) jumps 12% premarket after signing a binding agreement with GlaxoSmithKline (NYSE:GSK) to expand their existing collaboration to include the R&D of new therapies for influenza and other respiratory viruses.
https://seekingalpha.com/news/3662763-gsk-vir-bio-to-advance-therapies-for-respiratory-diseases
https://seekingalpha.com/symbol/GSK
https://seekingalpha.com/symbol/VIR
BMY & Rockefeller Uni = License Agreement - SARS-CoV-2 Neutralizing Monoclonal Antibody Combination
BMY & Rockefeller Uni = License Agreement - SARS-CoV-2 Neutralizing Monoclonal Antibody Combination
BMY & Rockefeller Uni = License Agreement - SARS-CoV-2 Neutralizing Monoclonal Antibody Combination
Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
02/03/2021CATEGORY:
NEW YORK--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and The Rockefeller University today announced that they have entered into a definitive agreement under which Bristol Myers Squibb has been granted a global exclusive license to develop, manufacture and commercialize Rockefeller’s novel monoclonal antibody (“mAb”) duo treatment that neutralizes the SARS-CoV-2 virus for therapy or prevention of COVID-19.
SARS-CoV-2 mAb Combo
About SARS-CoV-2 mAb Combo
Rockefeller has discovered two complementary antibodies to the SARS-CoV-2 spike protein that synergistically neutralize the virus in vitro and in animal models. The two antibodies have shown activity against several known SARS-CoV-2 mutants and it is believed that their co-administration could reduce the possibility of mutant virus escape. The two antibodies are potentially unique as pertains to their long half-life in humans and high affinity for the spike protein. The longer half-life has been enabled by leveraging Xencor’s Fc engineering technology.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.
Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company.
About The Rockefeller University
The Rockefeller University is the world’s leading biomedical research university and is dedicated to conducting innovative, high-impact research to improve the understanding of life for the benefit of humanity. The university’s unique approach to science, with only 70 faculty, each selected for pursuit of highly innovative ideas, has led to many of the world’s most revolutionary and transformative contributions to biology and medicine. During Rockefeller’s 120-year history, Rockefeller scientists have won 26 Nobel Prizes, 24 Albert Lasker Medical Research Awards, and 20 National Medals of Science.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210203005253/en/
COVID-19 research at Rockefeller
https://covid-19-research.rockefeller.edu/
Lilly teams up with Vir Bio/GSK to evaluate bamlanivimab with VIR-7831 in COVID-19
BMY & Rockefeller Uni = License Agreement - SARS-CoV-2 Neutralizing Monoclonal Antibody Combination
Lilly teams up with Vir Bio/GSK to evaluate bamlanivimab with VIR-7831 in COVID-19
Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
January 27, 2021 Download PDF
INDIANAPOLIS and SAN FRANCISCO and LONDON, Jan. 27, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19. Lilly has expanded its ongoing BLAZE-4 trial to evaluate the administration of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (also known as GSK4182136) 500mg, two neutralizing antibodies that bind to different epitopes of the SARS-CoV-2 spike protein. This unique collaboration marks the first time that monoclonal antibodies from separate companies will be brought together to explore potential outcomes.
bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
Important Information about bamlanivimab
Bamlanivimab has not been approved by the FDA for any use. It is not known if bamlanivimab is safe and effective for the treatment of COVID-19.
Bamlanivimab is authorized under an Emergency Use Authorization only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of bamlanivimab under Section 564(b)(1) of the Act, 21 U.S.C § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Healthcare providers should review the Fact Sheet for information on the authorized use of bamlanivimab and mandatory requirements of the EUA. Please see the FDA Letter of Authorization, Fact Sheet for Healthcare Providers, and Fact Sheet for Patients, Parents, and Caregivers (English) (Spanish).
Authorized Use and Important Safety Information
Bamlanivimab 700 mg injection is authorized for use under EUA for treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.
About BLAZE-4
BLAZE-4 (NCT04634409) is a randomized, double-blind, placebo-controlled trial designed to assess the efficacy and safety of bamlanivimab alone, and bamlanivimab with other neutralizing antibodies including VIR-7831 (GSK4182136) versus placebo for the treatment of symptomatic COVID-19 in the outpatient setting. Across all treatment arms, the trial will enroll an estimated 1,000 participants in the United States and Puerto Rico.
About bamlanivimab
Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.
Lilly has successfully completed a Phase 1 study of bamlanivimab in hospitalized patients with COVID-19 (NCT04411628). A Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is ongoing. In addition, bamlanivimab is being tested in the National Institutes of Health-led ACTIV-2 study in ambulatory COVID-19 patients.
Bamlanivimab is authorized in the U.S. for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization. Bamlanivimab should be administered as soon as possible after a positive COVID-19 test and within 10 days of symptom onset.
About etesevimab
Etesevimab (LY-CoV016, also known as JS016) is a recombinant, fully human monoclonal neutralizing antibody, which specifically binds to the SARS-CoV-2 surface spike protein receptor binding domain with high affinity and can block the binding of the virus to the ACE2 host cell surface receptor. Point mutations were introduced into the native human IgG1 antibody to mitigate effector function. Lilly licensed etesevimab from Junshi Biosciences after it was jointly developed by Junshi Biosciences and Institute of Microbiology, Chinese Academy of Science (IMCAS). Junshi Biosciences leads development in Greater China, while Lilly leads development in the rest of the world.
Lilly has successfully completed a Phase 1 study (NCT04441931) of etesevimab in healthy U.S. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity. A Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing. Junshi Biosciences has completed a similar Phase 1 study in healthy volunteers in China and has initiated Phase 1b/2 trials in COVID-19 patients globally.
About VIR-7831 / GSK4182136
VIR-7831 (GSK4182136) is an investigational dual-action monoclonal antibody. Preclinical data suggest it has the potential to both block viral entry into healthy cells and clear infected cells. The antibody binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 (the virus which causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. VIR-7831 also has been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.
The COMET clinical development program for VIR-7831 includes a planned Phase 3 trial for the prevention of symptomatic infection. VIR-7831 is also being evaluated in a sub-trial of the National Institutes of Health's (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Program Phase 3 clinical trial. This trial is designed to evaluate the safety and efficacy of VIR-7831 for the treatment of hospitalized adults with COVID-19.
To learn more about Lilly, please visit us at www.lilly.com
For further information please visit www.gsk.com/about-us.
For more information, please visit www.vir.bio.
View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-vir-biotechnology-and-gsk-announce-first-patient-dosed-in-expanded-blaze-4-trial-evaluating-bamlanivimab-ly-cov555-with-vir-7831-gsk4182136-for-covid-19-301216017.html
Lilly teams up with Vir Bio/GSK to evaluate bamlanivimab with VIR-7831 in COVID-19
Jan. 27, 2021 7:07 AM ET Eli Lilly and Company (LLY) By: Mamta Mayani, SA News Editor
- Eli Lilly (NYSE:LLY), Vir Biotechnology (NASDAQ:VIR) and GlaxoSmithKline (NYSE:GSK) have collaborated to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate symptoms.
Your COVID-19 Treatment Journey: Our Antibodies Might Help
https://www.lilly.com/news/stories/covid19-treatment-monoclonal-antibodies-infusion-resources
https://seekingalpha.com/symbol/LLY
Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc
Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc
Lilly teams up with Vir Bio/GSK to evaluate bamlanivimab with VIR-7831 in COVID-19
Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader
February 03, 2021 Download PDF Adds high-growth commercial franchise to Neuroscience portfolio with Epidiolex®, the first and only FDA-approved prescription cannabidiol medicine and a potential near-term blockbuster
Enhanced product diversification of combined company expected to provide accelerated double-digit revenue growth
Anticipated to be accretive in first full year of combined operations and substantially accretive thereafter
Conference call today at 8:30 AM ET
DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or $6.7 billion net of GW cash. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close in the second quarter of 2021.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious diseases — often with limited or no options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep and movement disorders, and in oncology, including hematologic malignancies and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX® (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX® for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia.
https://www.jazzpharma.com/science/pipeline/
Jazz to acquire GW Pharma in cash-and-stock deal valued at $7.2B
Feb. 03, 2021 8:03 AM ETJazz Pharmaceuticals plc (JAZZ)By: Dulan Lokuwithana, SA News Editor13 Comments
- Jazz Pharmaceuticals (NASDAQ:JAZZ) is trading ~5.3% lower in the premarket after announcing that it has agreed to acquire GW Pharmaceuticals plc (NASDAQ:GWPH) for $220.00 per American Depositary Share.
https://seekingalpha.com/news/3657703-jazz-to-acquire-gw-pharma-in-cash-and-stock-deal-valued-at-72b
https://seekingalpha.com/symbol/JAZZ
https://seekingalpha.com/symbol/GWPH
Deals
Jazz Pharma to Buy Cannabinoid-Drug Maker for $7.2 Billion
By Timothy Annett and Tiffany Kary
February 3, 2021, 7:50 AM EST Updated on February 3, 2021, 10:25 AM EST
- Terms represent 50% premium for U.K.-based GW Pharmaceuticals
- GW’s Epidiolex was first cannabis-derived drug cleared by FDA
GW is a developer of cannabinoid-based medications for cancer pain, multiple sclerosis and other conditions. Photographer: Jason Alden/Bloomberg https://www.bloomberg.com/news/articles/2021-02-03/jazz-pharmaceuticals-to-buy-gw-for-7-2-billion-in-cash-stock?srnd=premium
VERACYTE TO ACQUIRE DECIPHER BIOSCIENCES
Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc
Affimed Announces Collaboration with Roche
VERACYTE TO ACQUIRE DECIPHER BIOSCIENCES Feb 3, 2021 PDF Version
Further solidifies global leadership in differentiated, genomics-driven cancer diagnostics
Expands TAM with presence in 7 of the 10 most common cancers
Expected to accelerate revenue growth
Tina Nova, Ph.D., Decipher Biosciences’ president and CEO, has left Veracyte’s board and will become Veracyte’s GM, urologic cancers
Investor conference call and webcast today at 8:00 a.m. Eastern Time
SOUTH SAN FRANCISCO, Calif., & SAN DIEGO, Calif.--(BUSINESS WIRE)--Feb. 3, 2021-- Veracyte, Inc. (Nasdaq: VCYT) and Decipher Biosciences, Inc., a commercial-stage precision oncology company focused on urologic cancers, today announced they have entered into a definitive agreement through which Veracyte will acquire Decipher, further solidifying Veracyte’s global leadership in the genomic cancer diagnostics market while accelerating revenue growth.
About Decipher Bioscience
Decipher Biosciences is a commercial-stage precision oncology company committed to improving patient care, initially focused on urologic cancers. Decipher’s novel prostate cancer genomic test, Decipher Prostate, provides valuable information about the underlying biology of a patient’s tumor, assisting physicians in their selection of an optimal therapy. Decipher’s differentiated approach measures the biological activity of a patient’s entire tumor genome, known as whole transcriptome analysis, and applies proprietary machine learning algorithms to help physicians improve therapy selection and accelerate adoption of new therapies into the standard of care. Decipher Biosciences is headquartered in San Diego, California.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in thyroid cancer, lung cancer, breast cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping test is in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210203005354/en/
Veracyte to acquire Decipher Biosciences
Feb. 03, 2021 7:42 AM ETVeracyte, Inc. (VCYT)By: Khyathi Dalal, SA News Editor
- Veracyte (NASDAQ:VCYT) and Decipher Biosciences (DECI), commercial-stage precision oncology company focused on urologic cancers, inked a definitive acquisition agreement under which former will acquire the latter thereby solidifying Veracyte's global leadership in the genomic cancer diagnostics market while accelerating revenue growth.
https://seekingalpha.com/news/3657691-veracyte-to-acquire-decipher-biosciences
https://seekingalpha.com/symbol/VCYT
Affimed Announces Collaboration with Roche
Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc
Affimed Announces Collaboration with Roche
Affimed Announces Collaboration with Roche to Study AFM24 in Combination with PD-L1 Checkpoint Inhibitor in EGFR Expressing Solid Tumors
Press Release - February 3, 2021
Heidelberg, Germany, February 3, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has entered into a clinical research collaboration with Roche to explore the combination of Affimed’s innate cell engager (ICE®) AFM24 with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®).
Affimed’s innate cell engager (ICE®) AFM24 with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®).
Our Pipeline
Diverse pipeline of innate cell engagers designed to activate innate immunity
A number of clinical and preclinical programs are in development based on the ROCK® platform and our tetravalent bispecific immune cell engagers have already shown a favorable safety profile and promising signs of therapeutic efficacy.
https://www.affimed.com/rock-platform/pipeline/
TECENTRIQ may work with your immune system to fight cancer
Affimed and Roche collaborate to study AFM24 in solid tumors
Feb. 03, 2021 7:03 AM ET
By: Dulan Lokuwithana, SA News Editor
- Affimed N.V. (NASDAQ:AFMD) has surged ~10.6% in the premarket after announcing that it has entered a research collaboration with Roche (OTCQX:RHHBY) to study its innate cell engager (ICE®) AFM24 with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®).
https://seekingalpha.com/news/3657663-affimed-and-roche-collaborate-to-study-afm24-in-solid-tumors
https://seekingalpha.com/symbol/AFMD
https://seekingalpha.com/symbol/RHHBY
BiotechVortex™
Gilead and Vir Biotechnology Establish Clinical Collaboration
Gilead and Vir Biotechnology Establish Clinical Collaboration
Gilead and Vir Biotechnology Establish Clinical Collaboration
January 12, 2021
Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
-- First Phase 2 Clinical Trial to Combine Immunomodulation and Antigen Suppression Approaches in HBV Cure Research --
FOSTER CITY, Calif. & SAN FRANCISCO--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ: GILD) and Vir Biotechnology, Inc. (NASDAQ: VIR) today announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus (HBV).
Gilead and Vir Biotechnology Establish Clinical Collaboration
The companies plan to initiate a Phase 2 trial evaluating combination therapy for both treatment-experienced and treatment-naïve people living with HBV. The multi-arm trial will evaluate different combinations of selgantolimod, Gilead’s investigational TLR-8 agonist; VIR-2218, Vir’s investigational small interfering ribonucleic acid (siRNA); and a commercially-sourced, marketed PD-1 antagonist. People in the trial with HBV treatment experience may also receive Gilead’s Vemlidy® (tenofovir alafenamide fumarate, TAF). The primary outcome of the study will be the proportion of patients achieving a functional cure, defined as an off-therapy loss of hepatitis B surface antigen (HBsAg) and HBV DNA from the serum.
Both companies retain full rights to their individual product candidates and will discuss the potential path forward for any future combination studies based on the outcome of the Phase 2 trial.
VEMLIDY
INDICATION
VEMLIDY is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.
Please click here to see full Prescribing Information for VEMLIDY, including BOXED WARNING.
Please see Important Facts about VEMLIDY, including important warnings.
For more information, please visit www.vir.bio.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
Tue January 12, 2021 8:00 AM|GlobeNewswire|About: GILD, VIR
– First Phase 2 clinical trial to combine immunomodulation and antigen suppression approaches in HBV cure research –
FOSTER CITY, Calif. and SAN FRANCISCO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (GILD) and Vir Biotechnology, Inc. (VIR) today announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus (HBV).
Gilead and VIR Biotechnology tie up in chronic hepatitis B virus cure setting
Jan. 12, 2021 8:12 AM ET Gilead Sciences, Inc. (GILD) By: Aakash Babu, SA News Editor1 Comment
- Gilead Sciences (NASDAQ:GILD) and Vir Biotechnology (NASDAQ:VIR) announces that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus (HBV).
https://seekingalpha.com/symbol/GILD
https://seekingalpha.com/symbol/VIR
Lilly and Merus NV Announce Collaboration
Gilead and Vir Biotechnology Establish Clinical Collaboration
Gilead and Vir Biotechnology Establish Clinical Collaboration
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
January 19, 2021 Download PDF
INDIANAPOLIS and UTRECHT, The Netherlands, Jan. 19, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a clinical-stage oncology company developing multi-specific antibodies, today announced a research collaboration and exclusive license agreement that will leverage Merus' proprietary Biclonics® platform along with the scientific and rational drug design expertise of Loxo Oncology at Lilly to research and develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies.
For additional information, please visit Merus' website, www.merus.nl and https://twitter.com/MerusNV.
To learn more about Lilly, please visit us at www.lilly.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-and-merus-nv-announce-collaboration-to-discover-novel-t-cell-re-directing-bispecific-antibodies-301210513.html
Our Pipeline
The product candidates in the Merus pipeline are based on the Multiclonics® format (full length human IgG antibodies). Our strategy employs the unique attributes of our proprietary bispecific antibodies and our patented screening technologies to engage and harness the power of the immune system to target tumor cells.
https://seekingalpha.com/symbol/LLY
tislelizumab
Gilead and Vir Biotechnology Establish Clinical Collaboration
Biogen, Genentech team up for a new neurodegenerative biotech
Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene
Jan 11, 2021
- Agreement expands Novartis Oncology portfolio, adding late-stage PD-1 for monotherapy and potential proprietary PD-1 combinations, driving mid- and long-term growth
- Novartis secures development and commercialization rights in North America, Europe, and Japan
- Accelerates Novartis immuno-oncology combination strategy with multiple potential tislelizumab plus Novartis therapy combinations
- Tislelizumab already approved for patients with classical Hodgkin’s lymphoma and metastatic urothelial carcinoma in China; 15 registration-enabling clinical trials under way in non-small cell lung cancer (NSCLC) and other solid tumors
Basel, January 11, 2021 — Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene, Ltd. in major markets outside of China, accelerating the potential for Novartis to enter the large and growing checkpoint inhibitor field. Tislelizumab is an anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells.
tislelizumab
Tislelizumab is approved by the China National Medical Products Administration (NMPA) as a treatment for certain patients with classical Hodgkin’s lymphoma and metastatic urothelial carcinoma. In addition, BeiGene has filed three supplemental new drug applications for tislelizumab in China for first-line treatment of patients with advanced squamous NSCLC in combination with chemotherapy, first-line treatment of patients with advanced non-squamous NSCLC in combination with chemotherapy, and previously treated unresectable HCC.
Find out more at https://www.novartis.com.
BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab
Mon January 11, 2021 4:30 PM|Business Wire|About: BGNE
Novartis to co-develop and commercialize tislelizumab in North America, Japan, EU, and six other European countries
BeiGene (BGNE) to receive $650 million upfront payment and is eligible to receive up to $1.55 billion in potential regulatory and sales milestone payments plus royalties on product sales
BeiGene has the option to co-detail tislelizumab in North America
Both parties have freedom to conduct combination trials globally
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)-- BeiGene, Ltd.
https://seekingalpha.com/symbol/BGNE
https://seekingalpha.com/symbol/NVS
BeiGene, Novartis in Pact to develop tislelizumab for cancer settings
Jan. 11, 2021 4:47 PM ET BeiGene, Ltd. (BGNE)
By: Vandana Singh, SA News Editor
- BeiGene (NASDAQ:BGNE) has announced a collaboration and license agreement with Novartis Pharma (NYSE:NVS) for the development, manufacture and commercialization of BeiGene’s anti-PD-1 antibody tislelizumab. https://seekingalpha.com/news/3650509-beigene-novartis-in-pact-to-develop-tislelizumab-for-cancer-settings
https://www.beigene.com/science-and-product-portfolio/pipeline/tislelizumab
Biogen, Genentech team up for a new neurodegenerative biotech
Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health
Biogen, Genentech team up for a new neurodegenerative biotech
Biogen, Genentech team up for a new neurodegenerative biotech
Jan. 11, 2021 12:40 PM ET Roche Holding AG (RHHBY) By: Vandana Singh, SA News Editor
- Atalanta Therapeutics launches today with a Series A financing exclusively by F-Prime Capital.
Atalanta Therapeutics Launches With $110 Million to Pioneer RNAi Therapeutics for Neurodegenerative Diseases
Mon January 11, 2021 6:00 AM|Business Wire|About: BIIB, JNP
- Announces strategic collaborations with Biogen, Genentech to develop RNAi therapeutics for neurodegenerative diseases -
- Founders are world-leading experts in RNA interference, including Nobel (NLCI) laureate Craig Mello -
- Company has assembled a first-class management team of industry veterans helmed by CEO Alicia Secor -
BOSTON--(BUSINESS WIRE)-- Atalanta Therapeutics,
Preclinical research published in Nature Biotechnology has shown that branched siRNA can achieve unparalleled distribution in the CNS, including deep brain structures, and prolonged duration of effect.
For more information, visit www.atalantatx.com
F-Prime is headquartered in Cambridge, MA, with offices in London, UK and San Francisco, CA. For more information, please visit fprimecapital.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005327/en/
Biogen, Genentech and F-Prime power new neurodegenerative biotech to $110M unveiling
by Nick Paul Taylor | Jan 11, 2021 9:15am
https://seekingalpha.com/symbol/BIIB
https://seekingalpha.com/symbol/RHHBY
Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health
Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health
Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health
BIOGEN TO LAUNCH PIONEERING STUDY TO DEVELOP DIGITAL BIOMARKERS OF COGNITIVE HEALTH USING APPLE WATCH AND IPHONE
January 11, 2021 at 7:30 AM EST
- The study aims to identify digital biomarkers to help monitor cognitive performance and health including potentially detecting mild cognitive impairment, an early indicator of certain forms of dementia such as Alzheimer’s disease
- Cognitive health — the ability to think clearly, to learn and to remember — is an indicator of brain health and important to performing daily activities
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced a new virtual research study, in collaboration with Apple, to investigate the role Apple Watch and iPhone could play in monitoring cognitive performance and screening for decline in cognitive health including mild cognitive impairment (MCI).
information that may be important to investors on our website at www.biogen.com.
“Working in collaboration with Biogen, we hope this study can help the medical community better understand a person's cognitive performance by simply having them engage with their Apple Watch and iPhone,” said Jeff Williams, Apple’s chief operating officer. “We’re looking forward to learning about the impact our technology can have in delivering better health outcomes through improved detection of declining cognitive health.”
https://www.biogen.com/en_us/home.html
Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone
Mon January 11, 2021 7:30 AM|GlobeNewswire|About: BIIB
Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health
Jan. 11, 2021 8:33 AM ET Biogen Inc. (BIIB) By: Vandana Singh, SA News Editor3 Comments
- Biogen (NASDAQ:BIIB)
https://www.biogen.com/en_us/pipeline.html
https://seekingalpha.com/symbol/BIIB
Chi-Med and Inmagene Announce Strategic Partnership
Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health
Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health
11 Jan 2021
Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases
Hong Kong, Shanghai, San Diego & Florham Park, NJ: Monday, January 11, 2021: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Inmagene Biopharmaceuticals (“Inmagene”) today announce a strategic partnership to further develop four novel preclinical drug candidates discovered by Chi-Med for the potential treatment of multiple immunological diseases. Funded by Inmagene, the companies will work together to move the drug candidates towards investigational new drug (“IND”) submission. If successful, Inmagene will then move the drug candidates through global clinical development.
For additional information about Inmagene Biopharmaceuticals, please visit www.inmagenebio.com.
Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases
Sun January 10, 2021 8:00 PM|GlobeNewswire|About: HCM
HONG KONG, SHANGHAI, China, SAN DIEGO & FLORHAM PARK, N.J., Jan. 10, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (HCM) (“Chi-Med”) (Nasdaq/AIM: HCM) and Inmagene Biopharmaceuticals (“Inmagene”)
Chi-Med and Inmagene ink deal to develop candidates in immunological diseases
Jan. 11, 2021 12:54 AM ET Hutchison China MediTech Limited (HCM) By: Mamta Mayani, SA News Editor
- Hutchison China MediTech (NASDAQ:HCM)
Sanofi to acquire Kymab, adding KY1005 to its pipeline
Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US
Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US
January 11 2021
Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L
Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L
*Continues to build on Sanofi’s leading presence in immunology aligned with strategy to pursue best-in-class treatments in defined areas
PARIS and CAMBRIDGE, UK – January 11, 2021 – Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, have entered into an agreement under which Sanofi will acquire Kymab for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones.
For more information on Kymab please see http://www.kymab.com. Kymab and IntelliSelect are trademarks of Kymab Limited.
KY1005: Promising antibody for inflammatory disorders
In August 2020, Kymab announced that KY1005 met both primary endpoints in a Phase 2a trial studying moderate to severe atopic dermatitis patients whose disease is inadequately controlled with topical corticosteroids. KY1005 demonstrated a consistent treatment effect versus placebo across various key endpoints, including in the Eczema Area and Severity Index (EASI) and additional objective clinical measures.
“This acquisition aligns with our strategy of targeting fundamentally important disease pathways. We believe that OX40L, a key immune regulator, has the potential to rebalance the immune system without suppressing it, providing a promising new approach to treating a range of immune-mediated diseases,” said John Reed, M.D. Ph.D., Global Head of Research & Development at Sanofi.
Kymab’s pipeline also includes the oncology asset KY1044, an ICOS agonist monoclonal antibody, currently in early Phase 1/2 development as monotherapy and in combination with an anti-PD-L1. The acquisition also provides Sanofi with access to new antibody technologies and research capabilities.
Sanofi to buy Kymab for $1.45B
Jan. 11, 2021 3:30 AM ETSanofi (SNY)By: Mamta Mayani, SA News Editor
- Sanofi (NASDAQ:SNY) to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L.
https://seekingalpha.com/news/3650134-sanofi-to-buy-kymab-for-1_45b
https://seekingalpha.com/symbol/SNY
Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US
Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US
Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US
Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National Surveillance Infrastructure
With support from the Centers for Disease Control and Prevention (CDC), Illumina and Helix have already identified more than 50 cases of the new variant in the US
SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (Nasdaq: ILMN) and Helix today announced a collaboration to augment national surveillance infrastructure in the US to track the emergence and prevalence of novel strains of SARS-CoV-2 with support from the CDC. The combination of Illumina’s sequencing technology and expertise and Helix’s national COVID-19 testing footprint will significantly expand the country’s existing surveillance efforts to detect and characterize emerging variants of SARS-CoV-2.
To learn more, visit www.illumina.com
https://seekingalpha.com/symbol/ILMN
Learn more at www.helix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210105006007/en/
Illumina gets CDC backing to track emergence of new COVID-19 strains
Jan. 09, 2021 1:55 PM ETIllumina, Inc. (ILMN)By: Dulan Lokuwithana, SA News Editor
Blacksmith Medicines launches with seed funding and a research collaboration with Lilly
Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US
ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology
Blacksmith Medicines launches with seed funding and a research collaboration with Lilly
-Blacksmith Medicines, a spin-out of Forge Therapeutics, is pioneering a novel metalloenzyme chemistry platform to create new immuno-oncology and inflammation medicines –
– Research collaboration combines Blacksmith’s innovative chemistry platform with Lilly’s research and development expertise for novel human metalloenzyme-targeted medicines; total potential deal value up to approximately $300M –
SAN DIEGO, California, January 8, 2021 – Blacksmith Medicines, Inc. (Blacksmith), a biotechnology company focused on creating novel medicines for immuno-oncology and inflammatory diseases by targeting human metalloenzymes, announced today that it has secured seed funding and has entered into a research collaboration with Eli Lilly and Company (Lilly). Lilly joins existing Blacksmith investors Evotec A.G., MP Healthcare Partners, MagnaSci Ventures, and Alexandria Venture Investments. Blacksmith is a spin-out of Forge Therapeutics, a leading antibiotic discovery company discovering therapies to combat the rise of drug resistance.
For further information, please visit the company’s website at www.BlacksmithMedicines.com
Blacksmith Medicines has developed a purpose-built platform focused on the discovery and development of small molecule inhibitors of metal-dependent enzymes. Over 30% of known enzymes are metalloenzymes, covering all major enzyme classes: oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. Metal ions, including magnesium, zinc, iron, manganese and copper are the essential ingredient in these metalloenzymes.
https://blacksmithmedicines.com/technology/
https://blacksmithmedicines.com/
Eli Lilly collaborates with Blacksmith Medicines in a deal worth $300M
Jan. 08, 2021 8:43 AM ET Eli Lilly and Company (LLY) By: Dulan Lokuwithana, SA News Editor1 Comment
https://seekingalpha.com/news/3649921-eli-lilly-collaborates-blacksmith-medicines-in-deal-worth-300m
Blacksmith Medicines Launches With Seed Funding and a Research Collaboration With Lilly
-Blacksmith Medicines, a spin-out of Forge Therapeutics, is pioneering a novel metalloenzyme chemistry platform to create new immuno-oncology and inflammation medicines -
- Research collaboration combines Blacksmith's innovative chemistry platform with Lilly's research and development expertise for novel human metalloenzyme-targeted medicines; total potential deal value up to approximately $300M -
https://seekingalpha.com/symbol/LLY
ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology
ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology
ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology
ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology
Los Angeles, CA, USA, January 7, 2021 – ImaginAb Inc., a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. (NYSE: PFE) to supply 89Zr CD8 Immuno-PET agent, which can be used to image CD8 T cells in cancer patients.
For more information about ImaginAb’s pipeline and technology, visit www.imaginab.com.
ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology
Thu January 7, 2021 3:00 AM|PR Newswire|About: PFE
LOS ANGELES, Jan. 7, 2021 /PRNewswire/ -- ImaginAb Inc., a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. (PFE) to supply 89Zr CD8 Immuno-PET agent, which can be used to image CD8 T cells in cancer patients.
View original content to download multimedia:http://www.prnewswire.com/news-releases/imaginab-announces-license-and-supply-agreement-with-pfizer-for-cd8-immunopet-technology-301202156.html
https://seekingalpha.com/symbol/PFE
ImaginAb inks supply deal with Pfizer for CD8 ImmunoPET technology in Cancer
Jan. 07, 2021 3:29 AM ETPfizer Inc. (PFE)By: Mamta Mayani, SA News Editor
PerkinElmer to Acquire Oxford Immunotec Global PLC
ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology
Roche renews partnership with Sysmex to deliver haematology testing solutions
Home / Investors / News releases News release details PerkinElmer to Acquire Oxford Immunotec Global PLC
PerkinElmer to Acquire Oxford Immunotec Global PLC
January 7, 2021 at 7:00 AM ESTPDF Version
- PerkinElmer to acquire Oxford Immunotec for USD 22.00 per share in cash
- Transaction expected to be completed in the first half of 2021
WALTHAM, Mass. & LONDON--(BUSINESS WIRE)--Jan. 7, 2021-- PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Oxford Immunotec Global PLC (NASDAQ: OXFD) ("Oxford Immunotec" or the “Company”) are pleased to announce they have reached an agreement on terms under which PerkinElmer will acquire Oxford Immunotec (the “Acquisition”). It is intended that the Acquisition will be implemented by means of a U.K. High Court of Justice-sanctioned scheme of arrangement under Part 26 of the U.K. Companies Act 2006 between Oxford Immunotec and its shareholders (the “Scheme”).
Additional information can be found at www.OxfordImmunotec.com.
Product Pipeline
Our Focus
Our research and development activities focus on developing proprietary tests for the management of immune-regulated conditions. Our current focus is on four key areas: chronic infections, transplantation, autoimmune and inflammatory disease, and immune-oncology.
http://www.oxfordimmunotec.com/north-america/science/product-pipeline/
http://www.oxfordimmunotec.com/north-america/
PerkinElmer to acquire Oxford Immunotec for $591M
Today, 7:14 AM
https://seekingalpha.com/symbol/PKI
Roche renews partnership with Sysmex to deliver haematology testing solutions
ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology
Roche renews partnership with Sysmex to deliver haematology testing solutions
Roche renews partnership with Sysmex to deliver haematology testing solutions
- This successful long-running partnership continues to evolve and bring haematology testing innovations to laboratories, globally
- The new agreement aims to utilise the IT systems to lead to improved clinical decision making and customer experience
- Blood disorders have a high impact, not only for patients but for society as a whole, accounting for a third of all central laboratory tests1
Basel, 25 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that, on 14 December, 2020, it signed a Global Business Partnership Agreement* (GBP) with Sysmex.
About the Roche and Sysmex partnership
In 1999, Sysmex and Roche entered into a Distributorship Sales and Service Agreement (DSS), under which Roche distributed Sysmex hematology products and provided services in overseas markets. This mutually beneficial arrangement has since advanced as demands for haematology testing have evolved, with greater focus on automation of manual processes and streamlining workflow, expanding the utility of haematological parameters so as to support diagnosis, monitoring and treatment across disease areas, beyond routine testing. In 2018, Roche and Sysmex entered into a non-exclusive collaboration agreement to offer Total Laboratory Solutions (TLS). This means that customers who want to purchase products for clinical chemistry, immunochemistry, and hematology testing from one vendor, could do so seamlessly with Roche and Sysmex.
For more information, please visit www.roche.com.
Roche extends partnership with Sysmex in haematology testing solutions
Jan. 25, 2021 3:02 AM ET Roche Holding AG (RHHBY) By: Mamta Mayani, SA News Editor
- Roche (OTCQX:RHHBY) renews its Global Business Partnership Agreement (GBP) with Sysmex.
https://www.sysmex.com/us/en/Pages/default.aspx
BiotechVortex™
Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact
Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact
Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact
January 06, 2021
Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors
SANTA MONICA, Calif. & OXFORD, England & SAN JOSE, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), and Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based therapies, announced that the companies have entered into a research collaboration to evaluate five novel targets for a number of hematologic and solid tumor indications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210106005129/en/
For more information on Oxford BioTherapeutics, please visit www.oxfordbiotherapeutics.com.
For more information on Kite, please visit www.kitepharma.com.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors
Wed January 6, 2021 8:00 AM| Business Wire| About: GILD
SANTA MONICA, Calif. & OXFORD, England & SAN JOSE, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), and Oxford BioTherapeutics Ltd. (OBT)
https://seekingalpha.com/symbol/GILD
Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact
Jan. 06, 2021 2:24 PM ET Gilead Sciences, Inc. (GILD)By: Vandana Singh, SA News Editor2 Comments
- Kite, a Gilead Company (GILD +3.1%) and Oxford BioTherapeutics have entered into a research collaboration to evaluate five targets for a number of hematologic and solid tumor indications, using latter's OGAP target discovery platform.
https://seekingalpha.com/news/3649376-gileads-kite-oxford-biotherapeutics-ink-immuno-oncology-pact
Biogen inks deal for ophthalmic gene therapy development
Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact
Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact
ViGeneron signs global collaboration agreement for ophthalmic gene therapy development
Tue January 5, 2021 2:00 AM|GlobeNewswire|About: BIIB
- Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target
- The companies will use ViGeneron’s proprietary vgAAV technology to efficiently transduce target cells via intravitreal injections
MUNICH, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- ViGeneron GmbH, a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc. (BIIB) (Nasdaq: BIIB, Cambridge, Mass., USA)
For further information, please visit www.vigeneron.com.
https://seekingalpha.com/symbol/BIIB
Pipeline
https://www.biogen.com/en_us/pipeline.html
Biogen inks deal for ophthalmic gene therapy development
Jan. 05, 2021 2:39 AM ET Biogen Inc. (BIIB)
By: Mamta Mayani, SA News Editor4 Comments
https://seekingalpha.com/news/3648630-biogen-inks-deal-for-ophthalmic-gene-therapy-development
Zai Lab and Cullinan Oncology Announce Strategic Collaboration
Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact
A2 Biotherapeutics Enters Into Collaboration Agreement With Merck
Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China
Mon December 28, 2020 7:30 AM|GlobeNewswire|About: ZLAB
- Zai Lab (ZLAB) to lead development and commercialization of CLN-081 in Greater China
- Cullinan will receive $20 million upfront, up to $211 million in future milestones, and royalties
- Zai Lab to join ongoing global trial for CLN-081
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited, an innovative commercial-stage biopharmaceutical company, and Cullinan Oncology
About CLN-081
CLN-081 is an orally available, small-molecule, next-generation, irreversible EGFR inhibitor designed to selectively target cells expressing mutant EGFR variants. CLN-081 is currently in a Phase 1/2a dose escalation and expansion trial evaluating oral, twice-daily administration of various doses in patients with NSCLC harboring EGFR Ex20ins mutations who have had at least one prior treatment with platinum-based chemotherapy or another approved standard therapy.
For additional information about the company, please visit www.zailaboratory.com
For additional information, please visit www.cullinanoncology.com.
https://seekingalpha.com/symbol/CGEM
https://www.cullinanoncology.com/
https://seekingalpha.com/symbol/ZLAB
Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China
December 28, 2020 at 7:30 AM ESTPDF Version
- Zai Lab to lead development and commercialization of CLN-081 in Greater China
- Cullinan will receive $20 million upfront, up to $211 million in future milestones, and royalties
- Zai Lab to join ongoing global trial for CLN-081
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and Cullinan Oncology, a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, today announced an exclusive license agreement for the development, manufacturing and commercialization of CLN-081 in Greater China.
A2 Biotherapeutics Enters Into Collaboration Agreement With Merck
BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER
A2 Biotherapeutics Enters Into Collaboration Agreement With Merck
A2 Biotherapeutics Enters Into Collaboration Agreement With Merck To Develop Allogeneic Cell Therapy For Solid Tumor Cancers
Wed December 23, 2020 10:07 AM|PR NewswirePR Newswire
AGOURA HILLS, Calif., Dec. 23, 2020 /PRNewswire/ -- A2 Biotherapeutics (www.a2bio.com)
https://www.a2bio.com/our-science
For more information, visit www.a2bio.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/a2-biotherapeutics-enters-into-collaboration-agreement-with-merck-to-develop-allogeneic-cell-therapy-for-solid-tumor-cancers-301197998.html
SOURCE A2 Biotherapeutics
https://seekingalpha.com/symbol/MRK
Merck, A2 Bio in development pact for allogeneic cell therapy candidates for cancer
Dec. 23, 2020 1:08 PM ETMerck & Co., Inc. (MRK)By: Vandana Singh, SA News Editor
BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER
BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER
BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER
BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER
Dec 22, 2020 PDF Version
WHIPPANY, N.J. & SAN FRANCISCO--(BUSINESS WIRE)--Dec. 22, 2020--
Bayer and Veracyte (Nasdaq: VCYT) today announced a new collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer. Through the program, Bayer will offer testing with Veracyte’s Afirma Xpression Atlas (XA) to identify underlying genomic drivers, including NTRK gene fusions, within patients’ tumors. The program will focus on patients with advanced or metastatic thyroid cancer that is radioactive iodine refractory (RAIR) who may potentially benefit from biomarker-driven therapies.
For more information, go to www.bayer.us.
For more information, please visit www.veracyte.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201222005138/en/
Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer
Tue December 22, 2020 8:15 AM|Business Wire|About: VCYT
WHIPPANY, N.J. & SAN FRANCISCO--(BUSINESS WIRE)-- Bayer and Veracyte (VCYT) (Nasdaq: VCYT)
https://seekingalpha.com/symbol/VCYT
https://seekingalpha.com/symbol/BAYZF
Veracyte and Bayer collaborate in precision oncology;
Dec. 22, 2020 11:34 AM ET
Veracyte, Inc. (VCYT)By: Dulan Lokuwithana,
SA News Editor
Aurinia inks deal for voclosporin in Europe and Japan with Otsuka Pharma
BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER
BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER
Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
DOWNLOAD AS PDFDECEMBER 17, 2020
- Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments -
- Agreement includes royalties of up to 20 percent on net sales payable to Aurinia -
VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of oral voclosporin for the treatment of Lupus Nephritis (LN) in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine.
About Voclosporin
Voclosporin is a novel therapy in development for patients with LN, an inflammation of the kidney which is one of the most serious complications of the autoimmune disease SLE. If left untreated, LN can lead to irreversible kidney damage, kidney failure or even death. Through an extensive clinical program, voclosporin has demonstrated superiority to the standard-of-care for LN.
Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
Thu December 17, 2020 4:00 AM|Business Wire|About: AUPH
- Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments -
- Agreement includes royalties of up to 20 percent on net sales payable to Aurinia -
VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (AUPH)
Learn more about Otsuka Pharmaceutical Company on its global website at https://www.otsuka.co.jp/en.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005216/en/
https://www.auriniapharma.com/
https://seekingalpha.com/symbol/AUPH
Lilly Announces Agreement to Acquire Prevail Therapeutics
ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma
Lilly Announces Agreement to Acquire Prevail Therapeutics
Lilly Announces Agreement to Acquire Prevail Therapeutics
December 15, 2020Download PDFAcquisition will establish a gene therapy program at Lilly, anchored by Prevail's portfolio of neuroscience assets, and will broaden Lilly's commitment to use novel modalities to attempt to address otherwise fatal genetic forms of neurodegenerative disease
INDIANAPOLIS and NEW YORK, Dec. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a definitive agreement for Lilly to acquire Prevail for $22.50 per share in cash (or an aggregate of approximately $880 million) payable at closing plus one non-tradable contingent value right ("CVR") worth up to $4.00 per share in cash (or an aggregate of approximately $160 million), for a total consideration of up to $26.50 per share in cash (or an aggregate of approximately $1.040 billion). The CVR is payable (subject to certain terms and conditions) upon the first regulatory approval of a product from Prevail's pipeline as set forth in more detail below. Prevail is a biotechnology company developing potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases.
To learn more about Lilly, please visit us at www.lilly.com.
https://www.prevailtherapeutics.com/our-science/#overview
https://seekingalpha.com/symbol/LLY
Veracyte broadens the collaboration with JNJ
ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma
Lilly Announces Agreement to Acquire Prevail Therapeutics
VERACYTE ANNOUNCES EXPANSION OF COLLABORATION WITH THE LUNG CANCER INITIATIVE AT JOHNSON & JOHNSON<
Dec 15, 2020 PDF Version
Collaboration to Focus on 9,000-Patient Clinical Trial for Development of Future Lung Cancer Early-Detection Tests
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 15, 2020-- Veracyte, Inc. (Nasdaq: VCYT) today announced it has expanded its long-term strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson1. The collaboration will include a focus on the NOBLE trial, a 9,000-patient, prospective, multicenter clinical study designed to distinguish genomic and other differences in lung cancer development and progression among patients with lung nodules detected by CT imaging.
Veracyte broadens the collaboration with JNJ in early cancer detection
Dec. 15, 2020 9:49 AM ET Veracyte, Inc. (VCYT)By: Dulan Lokuwithana, SA News Editor
https://seekingalpha.com/news/3644460-veracyte-broadens-collaboration-jnj-in-early-cancer-dete
https://seekingalpha.com/symbol/VCYT
https://seekingalpha.com/symbol/JNJ
For more information, please visit www.veracyte.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215005345/en/
PIPELINE
Reducing Unnecessary Surgeries and Informing Treatment Decisions in in cancer and other disease
https://www.veracyte.com/our-products/pipeline
ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma
ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma
ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma
ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and Singapore
DECEMBER, 14, 2020
- Hillhouse-backed Overland Pharmaceuticals to initially contribute $50 million to fund operations and development
LAUSANNE, Switzerland & SHANGHAI & BOSTON--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE:ADCT) and Overland Pharmaceuticals, a fully integrated biopharmaceutical company backed by Hillhouse Capital, today announced that they have jointly formed a new company, Overland ADCT BioPharma (CY) Limited, to develop and commercialize four of ADC Therapeutics’ antibody drug conjugate (ADC) product candidates for difficult-to-treat hematologic and solid tumors – loncastuximab tesirine (Lonca), ADCT-601, ADCT-602 and ADCT-901 – in greater China and Singapore. Overland Pharmaceuticals has invested $50 million in Overland ADCT BioPharma to fund operations, including development plans for approval of Lonca for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in the licensed territory.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201214005195/en/
For more information, please visit https://adctherapeutics.com/
https://seekingalpha.com/symbol/ADCT
https://www.overlandpharma.com/
OUR PIPELINE
https://www.overlandpharma.com/our-pipeline/
AstraZeneca buying Alexion in $39B cash and stock deal
Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing
ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma
AstraZeneca Agrees to Buy Alexion for $39 Billion
The deal would bolster the British drug giant’s footprint in rare diseases
By Jenny Strasburg and Joseph Walker
Updated Dec. 12, 2020 12:27 pm ET
LONDON— AstraZeneca AZN 0.71% PLC said it agreed to buy Boston-based Alexion Pharmaceuticals Inc. ALXN 1.78% for $39 billion in cash and stock, a move that would bolster the British drug giant’s footprint in rare diseases.
AstraZeneca to acquire Alexion bulking up rare disease portfolio
Dec. 12, 2020 11:52 AM ET
AstraZeneca PLC (AZN) By: Dulan Lokuwithana, SA News Editor
https://seekingalpha.com/news/3643893-astrazeneca-to-acquire-alexion-bulking-up-rare-disease-portfolio
https://seekingalpha.com/symbol/AZN
https://seekingalpha.com/symbol/ALXN
https://alexion.com/our-research/pipeline
Accelerating AstraZeneca’s strategic and financial development AstraZeneca to acquire Alexion This webinar and conference call for investors and analysts is being recorded 12 December 2020
https://www.astrazeneca.com/content/dam/az/PDF/2020/20201212_Call_Alxn_Cmb_prsn.pdf?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link
Gilead Sciences to Acquire MYR GmbH Thu December 10, 2020 8:00 AM|Business Wire|About: GILD
Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing
Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing
December 10, 2020
Gilead Sciences to Acquire MYR GmbH
– Gilead to Acquire Hepcludex™, a First-in-Class Entry Inhibitor, for Treatment of Chronic Hepatitis Delta Virus (HDV), Adding Immediate Revenue After Closing of Transaction –
– Hepcludex Was Conditionally Approved in Europe in July 2020 Based on Phase 2 Data and Submission for Accelerated Approval in United States is Anticipated in Second Half of 2021 –
– Acquisition Builds on Gilead’s Strength as a Global Leader in Virology and Liver Diseases with Addition of First Marketed Product for Treatment of HDV –
FOSTER CITY, Calif. & BAD HOMBURG, Germany--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and MYR GmbH, a German biotechnology company f
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005315/en/
Additional information about the agreement can be found at Gilead’s Investors page at http://investors.gilead.com.
For more information on MYR, please visit the company's website at www.myr-pharma.com.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
Gilead Sciences to Acquire MYR GmbH
Thu December 10, 2020 8:00 AM|Business Wire|About: GILD
https://seekingalpha.com/pr/18117705-gilead-sciences-to-acquire-myr-gmbh
https://seekingalpha.com/symbol/GILD
Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing
Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing
Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing
Thermo Fisher Scientific Further Expands Global Footprint for Drug Product Development and Commercial Manufacturing
WALTHAM, Mass., Dec. 9, 2020 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced it will further expand its footprint in North America and Europe for sterile drug product development and commercial manufacturing of critical medicines, therapies and vaccines.
https://corporate.thermofisher.com/en/home.html
https://www.thermofisher.com/us/en/home.html
Thermo Fisher Scientific Further Expands Global Footprint for Drug Product Development and Commercial Manufacturing
Wed December 9, 2020 8:00 AM|PR Newswire
WALTHAM, Mass., Dec. 9, 2020 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced it will further expand its footprint in North America and Europe for sterile drug product development and commercial manufacturing of critical medicines, therapies and vaccines.
For more information, please visit www.thermofisher.com.
https://seekingalpha.com/symbol/TMO
Thermo Fisher Scientific and Innoforce Partner to Establish Biologics and Steriles Drug Manufacturing Facility in China
Fri November 6, 2020 6:00 AM|PR Newswire|About: TMO
For more information, please visit www.innoforcepharma.com.
BiotechVortex™
中国生物制药向科兴中维注资5.15亿美元，持股15.03% 2020-12-7
Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel
Y-mAbs, inks distribution pact with Takeda for nerve cell cancer meds, Danyelza & omburtamab
Sino Biopharm secures room for future growth with US$515 million investment in Sinovac’s Covid-19 vaccine unit
Beijing-based generic drug maker buys 15 per cent stake in Sinovac Life Sciences, a unit of Nasdaq-listed pharmaceutical firm Sinovac Biotech
Deal comes ahead of major announcement from China to launch 600 million doses of Covid-19 vaccines for use this year
Eric Ng Published: 3:18pm, 7 Dec, 2020
http://www.sinobiopharm.com/index.html#/
中国生物制药向科兴中维注资5.15亿美元，持股15.03%
2020-12-7
2020年12月7日，中国生物制药发布公告称，连同其附属公司的全资附属公司香港俊领有限公司就以5.15亿美元向北京科兴中维生物技术有限公司（简称科兴中维）出资订立协议。于出资完成后，中国生物制药将于科兴中维的注册资本中拥有15.03%权益。科兴中维将于中国生物制药的财务报表中入账列为联营公司。
http://www.sinobiopharm.com/index.html#/news/newsdeatil?id=2630
Y-mAbs, inks distribution pact with Takeda for nerve cell cancer meds, Danyelza & omburtamab
Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel
Y-mAbs, inks distribution pact with Takeda for nerve cell cancer meds, Danyelza & omburtamab
- Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel
Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel
Dec 04, 2020PDF Version
NEW YORK and PETACH TIKVA, Israel, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB)
NEW YORK and PETACH TIKVA, Israel, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) (the “Company” or “Y-mAbs”) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment ofRead moreDec 04, 2020
Y-mAbs, inks distribution pact with Takeda for nerve cell cancer meds, Danyelza & omburtamab
Dec. 04, 2020 9:30 AM ETY-mAbs Therapeutics, Inc. (YMAB)By: Vandana Singh, SA News Editor
https://seekingalpha.com/symbol/YMAB
https://seekingalpha.com/symbol/TAK
About the Y-mAbs development pipeline of therapies
https://ymabs.com/research-development/pipeline/
Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel
Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel
Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel
Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology
Thu December 3, 2020 3:00 AM|PR Newswire
- Merck KGaA, Darmstadt, Germany and Artios will conduct collaborative research and Merck KGaA, Darmstadt, Germany shall have the right to opt into exclusive development and commercialization of compounds on up to 8 targets
- Artios to receive US$30 million in up-front and near-term payments, plus double-digit option fees and up to US$860 million total milestones per target
- Collaboration to leverage significant expertise and R&D resources of Merck KGaA, Darmstadt, Germany in the field of DNA Damage Response to identify and develop precision oncology medicines targeting nucleases
DARMSTADT, Germany, CAMBRIDGE, UK and NEW YORK, Dec. 3, 2020 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, a leading science and technology company and Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, today announced a global three year strategic research collaboration to discover and develop multiple precision oncology drugs.
View original content:http://www.prnewswire.com/news-releases/merck-kgaa-darmstadt-germany-and-artios-pharma-announce-a-global-strategic-collaboration-on-novel-dna-damage-response-targets-in-oncology-301185247.html
https://seekingalpha.com/symbol/MKGAY
https://www.artiospharma.com/science/#pipeline
December 3, 2020
Bioengineered Antibody-Toxin Fusion Proteins- FastPharming® System
Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract
Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel
iBio Selected to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins
Tue December 1, 2020 4:30 PM | Globe Newswire | About: IBIO
BRYAN, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (IBIO) (NYSEA:IBIO)
Bioengineered Antibody-Toxin Fusion Proteins
New line of attack against cancer
atbodies are differentiated by both their unique composition and novel mechanism of action, providing a new class of biologic as an innovative therapeutic solution for hard-to-treat and refractory cancer.
https://www.atbtherapeutics.com/atbody
under a Master Services Agreement with Belgium-based ATB Therapeutics (“atbtherapeutics”) to produce its bioengineered antibody-toxin fusion proteins using iBio’s FastPharming® System.
FastPharming® System
FastPharming®
Advantages of Plant Based Protein Production
https://www.ibioinc.com/technology/fastpharming
For more information, visit www.ibioinc.com.
https://seekingalpha.com/symbol/IBIO
For more information, visit www.atbtherapeutics.com.
BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years
Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract
Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract
BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years
Wed December 2, 2020 7:00 AM|PR Newswire|About: BDX
- Investment includes new manufacturing facility in Europe
FRANKLIN LAKES, N.J., Dec. 2, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company (BDX)) (NYSE: BDX)
The new manufacturing facility in Europe is expected to be operational by the end of 2023.
For more information on BD, please visit bd.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/bd-to-invest-1-2-billion-in-pre-fillable-syringe-manufacturing-capacity-over-next-four-years-301183330.html
12/02/2020
BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years
https://seekingalpha.com/symbol/BDX
Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract
Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract
Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract
Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extracts in Germany
Wed December 2, 2020 8:00 AM|Business Wire|About: TLRY
BERLIN & FRANKFURT, Germany--(BUSINESS WIRE)-- Tilray, Inc. (TLRY) (“Tilray” or the “Company”) (Nasdaq: TLRY), a leading company in the manufacture, research and distribution of medical cannabis, announced that it has entered into a co-promotion agreement with Hormosan for its full-spectrum cannabis extracts in Germany effective 1 January 2021.
"With Hormosan we have gained a partner that has excellent expertise and contacts in the field of pain therapy and neurology and will thus significantly increase the visibility of Tilray's full-spectrum cannabis extracts in the future," explains Sascha Mielcarek, Managing Director Europe at Tilray. “This will give physicians and patients even better access to our medical cannabis extracts while supporting our goal of contributing to improved care for patients with medical cannabis."
View source version on businesswire.com: https://www.businesswire.com/news/home/20201202005128/en/
HORMOSANSeltene Erkrankungen
in der Neurologie
https://www.hormosan.com/seltene_erkrankungen.html
BERLIN & FRANKFURT, Germany --(BUSINESS WIRE)--Dec. 2, 2020-- Tilray, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a leading company in the manufacture, research and distribution of medical cannabis, announced that it has entered into a co-promotion agreement with Hormosan for its full-spectrum
December 2, 2020
https://seekingalpha.com/symbol/TLRY
Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br
Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets
Wed December 2, 2020 8:00 AM|PR Newswire|About: ABBV
- Frontier eligible to receive up to $100 million in upfront and milestone payments within the first 12 months of collaboration
PR Newswire
NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Dec. 2, 2020 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, and Frontier Medicines, Corp.,
For more information, visit www.frontiermeds.com
For more information about AbbVie, please visit us at www.abbvie.com.
https://seekingalpha.com/symbol/ABBV
Science
https://frontiermeds.com/science/#chemoproteomics
Dec 02, 2020
NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Dec. 2, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Frontier Medicines, Corp., a precision medicine company drugging challenging protein targets to develop breakthrough medicines that change the course of human diseases, today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative small molecule therapeutics against high-interest, difficult-to-drug protein targets.
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
Fri November 27, 2020 7:30 AM|Business Wire|About: BIIB, SAGE
- Biogen and Sage enter into an agreement to jointly develop and commercialize zuranolone and SAGE-324 in the U.S.
- Biogen to receive exclusive license to develop and commercialize zuranolone and SAGE-324 outside of the U.S., excluding rights to zuranolone in Japan, Taiwan and South Korea
- Sage Therapeutics (SAGE) to receive $1.525 billion in cash comprised of an upfront payment of $875 million and a $650 million equity investment as well as potential milestone payments, profit sharing and royalties
- Sage to host conference call Monday, November 30 at 8:00 a.m. ET
- Biogen to host conference call Monday, November 30 at 9:00 a.m. ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (BIIB) (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), postpartum depression (PPD) and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201127005340/en/
Zuranolone is a next-generation positive allosteric modulator of the gamma-aminobutyric acid (GABAA) receptor. The GABAA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS), and contributes significantly to regulating CNS function. This mechanism of action is a novel approach that may enable a new class of antidepressants.
We routinely post information that may be important to investors on our website at www.biogen.com.
https://seekingalpha.com/symbol/BIIB
For more information, please visit www.sagerx.com.
https://seekingalpha.com/symbol/SAGE
https://www.sagerx.com/programs-research/pipeline/
November 27, 2020
BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br
BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel
BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel Immunotherapies
Wed November 25, 2020 7:45 AM|GlobeNewswire|About: BNTX
- Long-term collaboration underpins BioNTech’s strategy to leverage Artificial Intelligence (AI) and Machine Learning (ML) technologies to support the discovery and development of novel immunotherapies based on InstaDeep’s DeepChainTM technology platform
- BioNTech (NTGN) and InstaDeep to establish a joint AI Innovation Lab to advance a portfolio of enterprise-wide digital initiatives in the areas of drug discovery and design, protein engineering, and operations
MAINZ, Germany and LONDON, United Kingdom, November 25, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech”) and InstaDeep Ltd
For more information, please visit www.BioNTech.de.
To learn more, please visit www.instadeep.com.
https://seekingalpha.com/symbol/BNTX
Research
InstaDeep’s in-house research team contributes to the latest advancements in AI – from the fundamentals of machine learning to robotics and deep reinforcement learning. Our published research has been presented at world-leading conferences such as NeurIPS 2018.
https://www.instadeep.com/research/
25 November 2020
BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation ..
Schrödinger Announces a Collaboration with Bristol Myers Squibb
Schrödinger Announces a Collaboration with Bristol Myers Squibb
BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel
Schrödinger Announces a Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers Squibb
Mon November 23, 2020 6:30 AM|Business Wire|About: BMY, SDGR
Schrödinger to receive $55 million upfront; eligible to receive up to $2.7 billion in milestone payments plus royalties
NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced a discovery collaboration with Bristol Myers Squibb Company (NYSE: BMY) to discover, develop, and commercialize therapeutics in multiple disease areas.
To learn more, visit www.schrodinger.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201123005663/en/
https://seekingalpha.com/symbol/SDGR
https://seekingalpha.com/symbol/BMY
Schrödinger inks multi-target drug discovery deal with Bristol-Myers Squibb
https://www.schrodinger.com/pipeline
OneOncology Partners with Genentech
Schrödinger Announces a Collaboration with Bristol Myers Squibb
OneOncology Partners with Genentech
OneOncology Partners with Genentech to Bring Personalized Cancer Research to Patients at Community Oncology Sites
Mon November 23, 2020 6:15 AM|PR Newswire|About: RHHBY
MyTACTIC Precision Basket Trial is Scheduled to Launch in December 2020 at Community Oncology Centers Including OneOncology
PR Newswire
NASHVILLE, Tenn., Nov. 23, 2020 /PRNewswire/ -- OneOncology, the national partnership of independent oncology practices, and Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)
Genentech's new clinical trial -- Targeting Actionable Mutation Study in Cancer (MyTACTIC) -- aims to match patient populations with a targetable genomic alteration to a specific investigational agent.
View original content to download multimedia:http://www.prnewswire.com/news-releases/oneoncology-partners-with-genentech-to-bring-personalized-cancer-research-to-patients-at-community-oncology-sites-301178283.html
About OneOncology:
OneOncology is a national partnership of independent, community oncology practices working together to improve the lives of everyone living with cancer through a physician-led, data-driven, technology-powered and patient-centric model. OneOncology is comprised of leading community oncology practices representing over 475 providers practicing at nearly 175 sites of care across the United States.
https://seekingalpha.com/symbol/RHHBY
Merck to Acquire OncoImmune
Schrödinger Announces a Collaboration with Bristol Myers Squibb
OneOncology Partners with Genentech
Merck to Acquire OncoImmune
November 23, 2020 6:45 am EST
Acquisition adds to Merck’s suite of clinical programs in response to SARS-CoV-2/COVID-19
Merck will accelerate development of CD24Fc, a candidate for the treatment of patients with severe and critical COVID-19
KENILWORTH, N.J., & ROCKVILLE, Md.--(BUSINESS WIRE)-- Merck (NYSE: MRK)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201123005593/en/
Merck adds to suite of COVID-19 clinical programs through OncoImmune acquistion
Nov. 23, 2020 6:54 AM ETMerck & Co., Inc. (MRK)By: Gaurav Batavia, SA News Editor
https://seekingalpha.com/symbol/MRK
Visit www.oncoimmune.com.
BiotechVortex™
QIAGEN Collaborates with BioNTech on Companion Diagnostics Development
Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes
Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes
QIAGEN Collaborates with BioNTech on Companion Diagnostics Development for HPV-associated Squamous Cell Carcinoma of the Head and Neck
Wed November 18, 2020 4:05 PM|Business Wire|About: BNTX, QGEN
- QIAGEN and BioNTech (NTGN) to develop tissue-based therascreen® test covering a panel of HPV genotypes, paired with investigational treatment BNT113, to identify patients whose cancers are caused by HPV infections
- QIAGEN to pursue global regulatory approvals, including Premarket Approval from FDA for companion diagnostics
- Collaboration leverages QIAGEN´s global reach and market-leading position in companion diagnostics and HPV testing
HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)-- QIAGEN N.V. (QGEN)
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005908/en/
https://seekingalpha.com/symbol/QGEN
https://seekingalpha.com/symbol/BNTX
Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes
Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes
Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes
Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes
Thu November 19, 2020 6:45 AM|PR Newswire|About: LLY
BURGDORF, Switzerland and INDIANAPOLIS, Nov. 19, 2020 /PRNewswire/ -- Eli Lilly and Company (LLY) and Ypsomed (YPHDF) (SWX: YPSN) For the latest updates, visit http://www.lillydiabetes.com/
Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes
Additional information is available under www.ypsomed.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-and-ypsomed-collaborate-to-advance-an-automated-insulin-delivery-system-for-people-with-diabetes-301176401.html
November 19, 2020
Tags | Product
BURGDORF, Switzerland and INDIANAPOLIS , Nov. 19, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Ypsomed (SWX: YPSN) announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly 's connected diabetes solutions.
https://seekingalpha.com/symbol/LLY
Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in G
Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes
Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in G
Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in Greater China
Thu November 19, 2020 7:00 AM|Business Wire|About: PFE
NEW YORK & SHANGHAI & PRINCETON, N.J.--(BUSINESS WIRE)-- Pfizer, Inc. (PFE) and LianBio
For more information, please visit lianbio.com.
We routinely post information that may be important to investors on our website at www.pfizer.com.cn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005290/en/
https://www.lianbio.com/pipeline/
https://seekingalpha.com/symbol/PFE
Ultragenyx to build gene therapy manufacturing facility
Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders
Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in G
Ultragenyx Announces Plans to Build Large-scale Gene Therapy Manufacturing Facility to Support Pipeline of Therapies for Rare Diseases
Mon November 9, 2020 8:05 AM|GlobeNewswire|About: RARE
State-of-the-art facility to be located in Bedford, Massachusetts
NOVATO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx to build gene therapy manufacturing facility
Nov. 9, 2020 9:27 AM ET|About: Ultragenyx Pharmaceutical... (RARE)|By: Vandana Singh, SA News Editor
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
https://seekingalpha.com/symbol/RARE
Novartis buys Vedere Bio for $280M
Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders
Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders
Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company
Thu October 29, 2020 2:15 AM|PR Newswire
$150 million upfront with the remainder in early regulatory and clinical milestones for a total of $280 million
Newly formed Vedere Bio II will leverage an ocular gene therapy toolbox to develop a new pipeline of novel vision restoration and vision preservation therapies
PR Newswire
CAMBRIDGE, Mass., Oct. 29, 2020 /PRNewswire/ -- Vedere Bio, Inc. (Vedere Bio), a stealth-stage company focused on advancing photoreceptor-protein-based optogenetic therapies that are delivered to the retina intravitreally to restore functional vision, announced today that it has been acquired by Novartis.
Novartis buys Vedere Bio for $280M
https://seekingalpha.com/news/3627953-novartis-buys-vedere-bio-for-280m
View original content to download multimedia:http://www.prnewswire.com/news-releases/novartis-acquires-vedere-bio-a-novel-optogenetics-aav-gene-therapy-company-301162269.html
SOURCE Vedere Bio, Inc.
https://seekingalpha.com/symbol/NVShttps://seekingalpha.com/symbol/NVS
Novartis acquires Vedere Bio, adding novel optogenetic gene therapy technology for treating blindness
Oct 29, 2020
- Acquisition expands the Novartis footprint in ophthalmology and enhances the company’s position as an AAV-based gene therapy powerhouse.
- Novartis gains two pre-clinical optogenetic AAV gene therapy programs and novel delivery technology for treating inherited retinal dystrophies and geographic atrophy.
- Inherited retinal dystrophies, including advanced retinitis pigmentosa, affect greater than 2 million patients worldwide, and geographic atrophy affects approximately 5 million patients worldwide.
Basel, October 29, 2020
Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders
Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders
Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders
insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Wed October 28, 2020 7:00 AM|Business Wire|About: BMY
insitro to Receive $50 Million in Upfront Cash with Total Potential Deal Value Over $2.1 Billion
Collaboration to Advance Targets and Therapeutic Candidates
SAN FRANCISCO--(BUSINESS WIRE)-- insitro
For more information on insitro, please visit the company’s website at www.insitro.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201028005276/en/
Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders
Oct. 28, 2020 7:26 AM ET|About: Bristol-Myers Squibb Company (BMY)|By: Vandana Singh, SA News Editor
https://seekingalpha.com/symbol/BMY
Jazz Pharmaceuticals acquires SpringWorks Therapeutics' FAAH inhibitor program
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G
Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program
Mon October 26, 2020 7:30 AM|PR Newswire|About: JAZZ, SWTX
Strategically Expands Jazz's Mid-Stage Neuroscience Pipeline into a New Disease Area and Further Optimizes SpringWorks' Strategic Focus on Targeted Oncology
Jazz to Make Upfront Payment of $35 Million to SpringWorks with Potential Milestone Payments of Up to $375 Million
PR Newswire
DUBLIN and STAMFORD, Conn., Oct. 26, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) and SpringWorks Therapeutics, Inc. (SWTX)
For more information, please visit www.jazzpharmaceuticals.com
For more information, visit www.springworkstx.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-acquires-springworks-therapeutics-faah-inhibitor-program-301159303.html
https://www.springworkstx.com/pipeline/
https://www.jazzpharma.com/science/pipeline/
https://seekingalpha.com/symbol/JAZZ
https://seekingalpha.com/symbol/SWTX
October 26, 2020
Jazz Pharmaceuticals Acquires SpringWorks Therapeutics’ FAAH Inhibitor Program
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy
Fri October 23, 2020 8:00 AM|GlobeNewswire|About: RARE, SLDB
-Collaboration combines Solid’s differentiated microdystrophin construct and Ultragenyx’s HeLa PCL manufacturing platform for use with AAV8 and variants-
-Solid receives $40 million upfront via equity investment at a premium; up to $255 million in milestones plus royalty payments-
-Solid retains exclusive rights to all other uses of its microdystrophins, including its existing SGT-001 program-
NOVATO, Calif. and CAMBRIDGE, Mass., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (RARE)
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
For more information, please visit www.solidbio.com.
https://seekingalpha.com/symbol/RARE
https://www.ultragenyx.com/pipeline/
Toggle Summary Oct 23, 2020Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G
Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines
Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan
Mon October 12, 2020 4:05 PM|GlobeNewswire|About: ATNX
BUFFALO, N.Y., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Axis Therapeutics Limited, a joint venture between Athenex, Inc. (ATNX) and Xiangxue Life Sciences Limited (“XLifeSc”), focused on the research, development, and commercialization of T cell immunotherapy, today announced that it has entered into a research collaboration with PharmaEssentia Corporation (Taipei Exchange: 6446).
For more information, please visit: www.axistherapeutics.com.
For more information, please visit www.pharmaessentia.com .
For more information about XPH, visit www.xphcn.com.
For more information, please visit www.athenex.com.
https://seekingalpha.com/symbol/ATNX
Axis Therapeutics inks research pact with PharmaEssentia for cancer T-cell therapy
Oct. 12, 2020 4:20 PM ET|About: Athenex, Inc. (ATNX)|By: Vandana Singh, SA News Editor
Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines
Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines
Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines
Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines for Neurological Diseases, Including Amyotrophic Lateral Sclerosis
Tue October 6, 2020 10:00 AM|Business Wire|About: BIIB
Committed to expanding treatment for underserved genetic conditions, Scribe and Biogen to collaborate on the development of novel genetic medicines for neurodegeneration
ALAMEDA, Calif.--(BUSINESS WIRE)-- Scribe Therapeutics Inc., the company focused on engineering the most advanced platform for CRISPR-based genetic medicine, today announced a research collaboration with Biogen Inc. (BIIB) to develop and commercialize CRISPR-based therapies that address an underlying genetic cause of Amyotrophic Lateral Sclerosis (ALS).
To learn more about Scribe’s mission to rewrite the story of disease, visit www.scribetx.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005506/en/
Innovent Bio's expanded collaboration with Lilly for Tyvyt now effective
Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines
Innovent Bio's expanded collaboration with Lilly for Tyvyt now effective
Innovent Announces the Effectiveness of the Expanded Global Collaboration with Lilly on TYVYT® (sintilimab injection) Following the Expiration of HSR Act Waiting Period
Tue October 6, 2020 8:00 PM|PR Newswire|About: IVBIY
SAN FRANCISCO and SUZHOU, China, Oct. 6, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (IVBIY) ("Innovent") (HKEX: 01801)
For more information, please visit: www.innoventbio.com.
Innovent Bio's expanded collaboration with Lilly for Tyvyt now effective
Oct. 7, 2020 12:38 AM ET|About: Innovent Biologics, Inc. (IVBIY)|By: Mamta Mayani, SA News Editor
http://innoventbio.com/en/#/product/products
Takeda and Arrowhead Pharmaceuticals team up in rare liver disease
Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines
Innovent Bio's expanded collaboration with Lilly for Tyvyt now effective
Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
Thu October 8, 2020 7:30 AM|Business Wire|About: ARWR, TAK
− Potential first-in-class therapy designed to treat the underlying cause of liver disease associated with AATD
− Arrowhead is eligible to receive up to $1.04B including an upfront payment of $300M and potential development, regulatory and commercial milestones up to $740M
− Investigational medicine ARO-AAT to be co-developed and co-commercialized in the United States by Takeda (TKPHF) and Arrowhead under a 50/50 profit-sharing structure
− Takeda receives exclusive license to commercialize ARO-AAT outside the U.S.
− Arrowhead will hold a conference call and webcast today, Oct. 8, at 8:30 a.m. ET
OSAKA, Japan & PASADENA, Calif.--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (ARWR)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005340/en/
For more information, visit https://www.takeda.com.
https://www.takeda.com/investors/
For more information, please visit www.arrowheadpharma.com
https://seekingalpha.com/symbol/ARWR
Pipeline
Novel Drugs to
Treat Intractable Diseases
https://arrowheadpharma.com/pipeline/
Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
October 8, 2020 Osaka, JAPAN, and Pasadena, CALIF.
- Potential first-in-class therapy designed to treat the underlying cause of liver disease associated with AATD
- Arrowhead is eligible to receive up to $1.04B including an upfront payment of $300M and potential development, regulatory and commercial milestones up to $740M
- Investigational medicine ARO-AAT to be co-developed and co-commercialized in the United States by Takeda and Arrowhead under a 50/50 profit-sharing structure
- Takeda receives exclusive license to commercialize ARO-AAT outside the U.S.
- Arrowhead will hold a conference call and webcast today, Oct. 8, at 8:30 a.m. ET
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR)
BiotechVortex™
Bristol Myers Squibb to acquire Myokardia for $13.1B in cash
CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China
CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China
Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash
Mon October 5, 2020 6:30 AM|Business Wire|About: BMY, MYOK
Mavacamten Is a Potential First-in-Class Medicine with Compelling Data in the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Mavacamten Will Be a Medium- and Long-Term Growth Driver Presenting a Significant Commercial Opportunity upon Approval
Promising Portfolio of Pipeline Candidates Strengthens and Extends Bristol Myers Squibb’s Leading Cardiovascular Franchise
Expected to be Accretive to Non-GAAP Earnings Starting in 2023
NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (MYOK)
For more information about Bristol Myers Squibb, visit us at BMS.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005381/en/
Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash
10/05/2020CATEGORY:
Mavacamten Is a Potential First-in-Class Medicine with Compelling Data in the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Mavacamten Will Be a Medium- and Long-Term Growth Driver Presenting a Significant Commercial Opportunity upon Approval
Promising Portfolio of Pipeline Candidates Strengthens and Extends Bristol Myers Squibb’s Leading Cardiovascular Franchise
Expected to be Accretive to Non-GAAP Earnings Starting in 2023
NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire MyoKardia for $13.1 billion, or $225.00 per share in cash. The transaction was unanimously approved by both the Bristol Myers Squibb and MyoKardia Boards of Directors and is anticipated to close during the fourth quarter of 2020.
https://seekingalpha.com/symbol/MYOK
https://seekingalpha.com/symbol/BMY
CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China
CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China
CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China
CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China
Tue September 29, 2020 11:22 PM|Business Wire|About: LGND, PFE
- Pfizer (PFE) to invest $200 million in CStone shares and license CStone’s late-stage oncology asset sugemalimab (CS1001, PD-L1 antibody) in mainland China
- CStone to receive up to $280 million in milestone payments for sugemalimab, and additional royalties
- CStone and Pfizer to develop and commercialize additional late-stage oncology therapies in Greater China
SUZHOU, China--(BUSINESS WIRE)-- CStone Pharmaceuticals (CSPHF) (“CStone”, HKEX: 2616)] and Pfizer Investment Co. Ltd. ("Pfizer Investment") and Pfizer Corporation Hong Kong Limited ("Pfizer Hong Kong") (both of which are subsidiaries of Pfizer Inc.)
For more information about CStone, please visit: www.cstonepharma.com.
http://www.cstonepharma.com/en/
For more information, please visit www.pfizer.com.cn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929006175/en/
https://seekingalpha.com/symbol/PFE
https://seekingalpha.com/symbol/CSPHF
CSTONE PHARMACEUTICALS - B (2616)
https://www.hkex.com.hk/Market-Data/Securities-Prices/Equities/Equities-Quote?sym=2616&sc_lang=en
Roche doubles down on promising inflammation field with Inflazome buy
CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China
Roche doubles down on promising inflammation field with Inflazome buy
Inflazome Announces Acquisition by Roche
Mon September 21, 2020 2:00 AM|Business Wire|About: RHHBY
- Inflazome is a pioneering inflammasome company developing orally available NLRP3 inflammasome inhibitors to address clinical unmet needs across a wide variety of inflammatory diseases
- Acquisition of Inflazome gives Roche (RHHBY) full rights to the Inflazome portfolio
- Activation of the NLRP3 inflammasome in the body is implicated in many diseases caused by chronic, uncontrolled inflammation
- Inflazome shareholders received €380 million upfront, and are eligible to receive additional milestone payments
DUBLIN & CAMBRIDGE, England--(BUSINESS WIRE)
View source version on businesswire.com: https://www.businesswire.com/news/home/20200920005066/en/
https://www.cell.com/fulltext/S0092-8674%2810%2900075-9
https://seekingalpha.com/symbol/RHHBY
Roche doubles down on promising inflammation field with Inflazome buy
Sep. 26, 2020 12:30 AM ET|About: Roche Holding AG (RHHBY)|By: Douglas W. House, SA News Editor